

AD_____

Award Number: DAMD17-01-1-0721

TITLE: Quest: A New Approach to Molecular Staging of Tumors

PRINCIPAL INVESTIGATOR: Karen Stephens, Ph.D.

CONTRACTING ORGANIZATION: University of Washington
Seattle, Washington 98105-6613

REPORT DATE: August 2003

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20040311 126

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE August 2003	3. REPORT TYPE AND DATES COVERED Annual (30 Jul 2002 - 29 Jul 2003)	
4. TITLE AND SUBTITLE Quest: A New Approach to Molecular Staging of Tumors			5. FUNDING NUMBERS DAMD17-01-1-0721	
6. AUTHOR(S) Karen Stephens, Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Washington Seattle, Washington 98105-6613 E-Mail: millie@u.washington.edu			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited				12b. DISTRIBUTION CODE
13. ABSTRACT (Maximum 200 Words) Towards the goal of molecular diagnosis and staging of NF1-related tumors, we proposed to develop and validate a novel PCR-based method, termed QuEST, of rapid and quantitative identification of loci with increases or decreases in genomic copy number in MPNST. We have developed new assays that are sensitive and specific and allow the quantification of one gene copy versus two gene copies. The method was validated on constitutional DNA using assays that determined the copy number of the NF1 gene. This methodology will be used for both loss (deletion) of DNA and gain (amplifications) of DNA in tumor cell lines and primary tumors. Assays are in development for the target areas of chromosome 1p and 17q22-24. The amplification and loss of chromosomal material at these regions was confirmed by high resolution karyotyping in two neuroblastoma-derived cell lines that will be employed to test the methodology on tumor tissues. We have made significant progress in assay design for quantification of genomic losses and gains. Implementation of these assays will now test the usefulness of our idea of using QuEST for defining specific losses and gains in tumors.				
14. SUBJECT TERMS Tumor staging, biomarkers, quantitative PCR, laser capture microdissection				15. NUMBER OF PAGES 32
				16. PRICE CODE
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89)
Prescribed by ANSI Std. Z39-18
298-102

Table of Contents

Cover.....	1
SF 298.....	2
Table of Contents	3
Introduction.....	4
Body.....	4
Key Research Accomplishments.....	12
Reportable Outcomes.....	12
Conclusions.....	12
References.....	13
Appendices.....	15

Introduction

Lack of a definitive system for the diagnosis and staging of NF1-related tumors is a major obstacle to investigating the molecular basis of tumorigenesis, to our ability to assess prognosis, and consequently, to the rational design and application of stage-specific therapeutic agents (1-3). Locus-specific changes in copy number are a common feature of many types of tumors, including the neurofibromas and malignant peripheral nerve sheath (MPNST) that develop in individuals with NF1 (4-13). Gains or losses at a particular locus are potential biomarkers for the molecular diagnosis and grading of MPNST. Towards the goal of molecular diagnosis and staging of NF1-related tumors, we propose to develop and validate a novel PCR-based method, termed QuEST, for rapid and quantitative identification of loci with increases or decreases in genomic copy number in MPNST. The specific aims are (1) to develop a series of reference and target markers for quantitative assessment of gene copy number. This will involve selection, design and optimization of primers and QuEST reactions for reference and target loci. (2) to perform QuEST analysis on series of cell lines and MPNST samples for two target regions where copy number changes are associated with MPNST formation: amplification of 17q22-qter and deletion of 1p. (3) to determine the feasibility of coupling QuEST analysis with laser capture microdissection. This study has the potential of providing direct and precise methods to use in addressing issues important to diagnosis, treatment, and molecular analysis of MPNST.

Body

Research accomplishments associated with each task outlined in the Statement of Work are detailed below. We have obtained a one year no-cost extension to complete this project, because our timeline was significantly delayed due to the departure of a postdoctoral fellow who was working on this project. A new postdoctoral fellow (Dr. Wang) is now focusing on the development, optimization, and validation of assays and a new Research Associate (Ms. Vong) is implementing those assays on appropriate samples. With these two new professionals, we anticipate accelerating the timeline to complete the project within the next year. We made significant changes in the methodology of quantitative PCR to increase the sensitivity and precision.

Approved Statement of Work

- Task 1. Design and test a series of primers for analysis of both target loci and reference loci.
- Design and synthesize primers for genes in the target regions of chromosomes 1p and 17q22-24 and for reference loci.
 - Optimize the amplification reaction for each locus using non-tumor genomic DNA

Progress: We need the capability and sensitivity to determine if a locus or gene has no deletion (2 copies), one gene deletion (1 copy), two gene deletion (0 copies), or amplification (likely >10 copies). Two gene deletion and gene amplification are simple to detect using various methods of quantitative PCR. The difficulty is in reliably differentiating one versus two copies of a gene. Therefore, we have been focusing on developing the best assay to detect a one gene deletion. To determine which quantitative PCR methods were sensitive, we choose to develop an assay at intron 31 of the NF1 gene. To validate the assays we used DNA from normal individuals (2 NF1 genes) and DNA from NF1 patients with deletions involving the NF1 gene (1 NF1 gene). Initially, we tried using SYBR green (binds double stranded DNA) fluorescence as a method of detection during real-time PCR in the LightCycler instrument (Roche). There was considerable overlap between the crossing point values (Ct) for samples with one and two NF1 genes indicating that the assay was not as sensitive or specific as required (data not show). Secondly, we sought to increase specificity and sensitivity by using a NF1-specific fluorescently-labeled primer. We constructed a LUX primer (Invitrogen), which

is a hybrid primer comprised of NF1 specific sequences and anonymous sequences that are capable of fold-back annealing. LUX primers are touted as having high specificity because they only fluoresce at high temperatures when the fold backs are melted. We had multiple problems with LUX primers and decided to abandon that approach (data not shown). The third method we developed was precise, sensitive, and specific and involves SYBR green for detection, competitive quantitative PCR, and melting curve analysis as detailed below.



We chose to employ SYBR green for detection in combination with competitive PCR, which is the most suitable method of quantification when highly accurate determinations are required. We adapted and modified a method published by Ruiz-Ponte et al. (14). In this method, a known copy number of a competitor is introduced directly in the PCR mixture along with the target DNA of the patient/tumor. The competitor, which is almost identical to the target DNA but distinguishable by product length, is amplified with the same set of primers so that efficiency of amplification for the two amplicons is the same. Calibration curves of different competitor concentrations determines the optimal concentration that equals that of the target DNA. Figure 1 shows the melting curves of a normal control DNA samples (2 copies of NF1), where competitor and intron 31 are co-amplified with equal efficiency and the area under the curves are equal (roughly equivalent to peak height in this example). We constructed the competitor such that it would be amplified with the intron 31 primers, but have a different melting curve by replacing an internal TTT sequence with a CCC sequence. As expected, negative samples lacking human DNA did not amplify.

Figure 2 shows the melting curve of a patient with an NF1 deletion (1 copy of NF1) versus that of the normal control individual. Note that the amplitude of the melting curve of the NF1 amplicon for the deletion patient is less that of the competitor amplicon because there are fewer targets in the deleted patient's DNA. For precision, we use the peak areas of each melting curves for quantitation rather than peak height. A ratio of peak area of normal control (2 copies) over the peak area of the patient target DNA is calculated, see below.

(see figures on next page)

Figure 1. Melting curve analysis after competitive, quantitative PCR at NF1 intron 31 in genomic DNA of a normal control individual. The peaks representing the melting curve of the amplicon of the competitor and the amplicon of the patient's target DNA are indicated. The negative control without DNA shows evidence of amplification.



Figure 2. Melting curve analysis after competitive, quantitative PCR at NF1 intron 31 can differentiate one gene copy versus two gene copies. The results of two reactions are shown, closed circles represent target DNA from a normal control individual and closed squares represent target DNA from an NF1 patient with a deletion of one gene. The peaks representing the melting curve of the amplicon of the competitor and the amplicon of the patient's target DNA are indicated. The negative control without DNA shows evidence of amplification.



Once the concentration of competitor is determined for a certain concentration of the normal control DNA, it is essential that all subsequent reactions with unknown patient DNA samples contain exactly the same concentration of target DNA. Prior to the competitive quantitative PCR assay, we determine the exact concentration of each patient sample using real-time quantitative PCR at a different locus. We amplify the TPA (tissue plasminogen activator) gene on chromosome 12 in each patient and compare that to a standard curve using the normal control DNA. From this reaction, we can calculate exactly what volume of patient DNA must be added to the competitive quantitative PCR assay. An example of the TPA real-time PCR and standard curve is shown in Figure 3.

(see figure 3 on next page)

Figure 3. LightCycler real-time PCR at TPA locus showing standard curve. The upper panel shows the results of real-time PCR of the TPA locus of a dilution series of a normal control individual. The reaction consists of unlabeled primers and uses an internal labeled (fluorescence resonance energy transfer (FRET) probe for detection of product. The crossing point (Ct) is defined as the fractional cycle at which fluorescence begins to increase exponentially and is calculated by the LightCycler. Ct becomes larger as the number of TPA targets decreases. The lower panel shows the standard curve calculated from the above data. Note the low error and high correlation coefficient.



The competitive quantitative gene dosage assay we have developed for intron 31 of the NF1 gene is very precise and shows minimal variability. Figures 4 and 5 (see legends below and figures on next page) show melting curves for 6 replicates of an NF1 deletion patient and a normal control individual, respectively. The data will be analyzed as shown in the tables below. First, note the precision of the assay; the standard deviations are only 2% and 3% of the means of the assay for normal control individuals and deletion patients, respectively. As expected the ratio of NF1:competitor peak areas is essential 1.0 for samples with two copies of the NF1 gene and is 0.5 for samples with one copy of the NF1 gene. We have screened a large collection of NF1 deletion patients and normal individuals and found that there is no overlap of ratio values between these two populations.

Therefore, we have developed a sensitive and specific assay that differentiates reliably between one versus two copies of a gene. We are now applying this same assay to determine it's ability to quantitate amplified loci.

Replicates of competitive quantitative PCR for intron 33 of NF1
or normal control individual



No.	Area of NF1 peak	Area of Competitor Peak	Ratio	Mean Ratio	S.D.
1	3.219	2.957	1.088		
2	3.262	3.296	0.989		
3	3.097	3.255	0.951		
4	3.464	3.26	1.062		
5	3.433	3.278	1.047		
6	3.091	2.918	1.059		
				1.033	0.0211

Replicates of competitive quantitative PCR for intron 33 of NF1
for deleted patient

No.	Area of NF1 peak	Area of Competitor Peak	Ratio	Mean Ratio	S.D.
1	1.937	3.85	0.503		
2	2.103	3.68	0.571		
3	1.952	3.755	0.519		
4	2.052	3.356	0.611		
5	1.851	3.665	0.505		
6	1.934	3.33	0.580		
				0.548	0.0185

Figure 4. Melting curves of competitive quantitative PCR at NF1 intron 31 of 6 replicates of an NF1 deletion patient. Six curves (color replaced by grey tones for this report) are overlaid to demonstrate the precision and lack of variability in replicate samples.

Figure 5. Melting curves of competitive quantitative PCR at NF1 intron 31 of 6 replicates of a normal control individual. Six curves (color replaced by grey tones for this report) are overlaid to demonstrate the precision and lack of variability in replicate samples.



Task 2. Perform spectral karyotyping (SKY) of the MPNST- and neuroblastoma-derived cell lines. Months 1-12.

Progress: In collaboration with Dr. Karen Swisshelm, Department of Pathology, University of Washington, we have analyzed the karyotype of two of the neuroblastoma-derived cell lines. We have performed a routine metaphase G-banded karyotype, which was very informative in determining exactly which bands were deleted and or amplified. One line will be ideal for analysis of the amplified region of chromosome 1p and the other line for the deleted region of 17q22.24. Other regions of amplification and deletion were observed and may be targeted later in this project. Because this analysis was so informative, we do not plan to perform a SKY analysis unless our PCR results are inconsistent with the karyotype.

Dr. Stephens performed a comprehensive literature search and compilation of the genetic changes in NF1-associated peripheral nerve sheath tumors (see manuscript in Appendix). This review revealed that there are consistent regions of the genome that undergo gains and losses in MPNST. This review also underscored our choice of the 17q22-q25 region as one of frequent gains in chromosomal loci (74%).

Task 3. Validate the QuEST method by analysis of target and reference loci in DNA from tumor cell lines. Months 6-12.

- a. Perform QuEST analysis of genes in the target regions chromosomes 1p and 17q22-24 in DNA from MPNST- and neuroblastoma-derived cell lines. We anticipate analysis of 4 lines.
- b. Evaluate the results of QuEST compared to the SKY analysis.

Progress: This analysis is in progress. Now that the competitive quantitative PCR methodology has been validated, we are developing and optimizing similar assays for loci that span the 1p and 17q22-24 regions. Development and optimization of each assays includes:

- Choosing primer pairs for loci that are single-copy in the genome.
- Screening against the appropriate monochromosomal human-rodent hybrid cell line to ensure we are not amplifying related loci from other chromosomes
- Optimizing PCR reaction
- Developing competitor target DNA
- Titrating competitor target DNA to determine the concentration equivalent to the normal diploid DNA control target
- Performing real-time PCR at TPA locus for each tumor DNA sample (in reality, we will have 5 such loci as controls in case one of them is altered in the tumor sample). Determine the concentration to add to the competitive quantitative PCR assay.
- Performing competitive, quantitative PCR assay
- Analyzing data

As stated in the original Statement of Work, tasks 4-6 will be performed in the later period of the research project.

Task 4. Test the QuEST method by analysis of target and reference loci in DNA from tumors.

This awaits completion of the assays in the tumor cell lines. Anonymous MPNST DNA from NF1 patients are being collected from collaborators for these future assays.

Task 5. Determine the sensitivity of the QuEST method.
This await completion of Task 4.

Task 6. Couple QuEST with laser capture microdissection of archival MPNST.

After Dr. Wang has the assays developed and they are being implemented by Ms. Vong, he will begin performing laser capture microdissection of archival MPNST at the University of Washington Medical Center and assessing the quality of the DNA using the TPA assay. When this protocol is optimized, we will apply the assays for deletion of 17q22-q25 region in MPNST.

Key Research Accomplishments

- A comprehensive analysis and summary of genetic changes reported in NF1-associated peripheral nerve sheath tumors. These data were reported in a review article by Dr. Stephens that is in press (see Reportable Outcomes).
- Developed a specific and sensitive competitive, quantitative PCR methodology that can differentiate one copy from two copies in a genome.
- Employed real-time PCR of the TPA locus as a means of precise DNA quantification
- Validated the competitive, quantitative PCR methodology by assay of the NF1 locus in normal control individuals and NF1 deletion patients.
- Documented the reproducibility of the competitive, quantitative PCR method.
- Performed and analyzed high-resolution karyotype of the two neuroblastoma-derived cell lines that we will be using to validate the competitive, quantitative PCR method for analysis of DNA gains and losses in tumor tissue.

Reportable Outcomes

- Manuscript: Stephens K. Genetics of Neurofibromatosis 1-associated peripheral nerve sheath tumors. Cancer Invest, in press. (See proofs of article in appendix).
- Karyotypes of two neuroblastoma-derived cell lines.
- Development of competitive, quantitative PCR assays for differentiating one versus two copies of NF1 gene intron 31.

Conclusions

Towards the goal of molecular diagnosis and staging of NF1-related tumors, we proposed to develop and validate a novel PCR-based method, termed QuEST, for rapid and quantitative identification of loci with increases or decreases in genomic copy number in MPNST. We have performed a comprehensive literature search and compilation of the genetic changes in NF1-associated peripheral nerve sheath tumors. The implications of this analysis are that consistent regions of the genome frequently undergo gains and losses in NF1-associated MPNST. This phenomenon underscores the validity of our approach and increases the probability that it may be of clinical and/or research use. We have developed new assays that are sensitive and specific and allow the quantitation of one gene copy versus two gene copies. The method was validated

on constitutional DNA using assays that determined the copy number of the NF1 gene. This methodology will be used for both loss (deletion) of DNA and gain (amplifications) of DNA in tumor cell lines and primary tumors. Assays are in development for the target areas of chromosome 1p and 17q22-24. The amplification and loss of chromosomal material at these regions was confirmed by high resolution karyotyping in two neuroblastoma-derived cell lines that will be employed to test the methodology on tumor tissues. We have made significant progress in assay design for quantification of genomic losses and gains. Implementation of these assays will now test the usefulness of our idea of using QuEST for defining specific losses and gains in tumors.

References

1. Guillou, L., Coindre, J.M., Bonichon, F., Nguyen, B.B., Terrier, P., Collin, F., Vilain, M.O., Mandard, A.M., Le Doussal, V., Leroux, A. *et al.* (1997) Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. *J Clin Oncol*, **15**, 350-62.
2. Mandard, A.M., Petiot, J.F., Marnay, J., Mandard, J.C., Chasle, J., de Ranieri, E., Dupin, P., Herlin, P., de Ranieri, J., Tanguy, A. *et al.* (1989) Prognostic factors in soft tissue sarcomas. A multivariate analysis of 109 cases. *Cancer*, **63**, 1437-51.
3. Unnik, v.J.A.M. (1995) Classification and grading of soft-tissue sarcomas. In Patel, S.R. and Benjamin, R.S. (eds.), *Hematology/Oncology Clinics of North America*. W.B. Saunders Co, Philadelphia, Vol. 9, pp. 677-700.
4. Lothe, R.A., Saeter, G., Danielsen, H.E., Stenwig, A.E., Hoyheim, B., O'Connell, P. and Borresen, A.L. (1993) Genetic alterations in a malignant schwannoma from a patient with neurofibromatosis (NF1). *Pathol Res Pract*, **189**, 465-71; discussion 471-4.
5. Lothe, R.A., Slettan, A., Saeter, G., Brogger, A., Borresen, A.L. and Nesland, J.M. (1995) Alterations at chromosome 17 loci in peripheral nerve sheath tumors. *J. Neuropathol. Exp. Neurol.*, **54**, 65-73.
6. Lothe, R.A., Karhu, R., Mandahl, N., Mertens, F., Saeter, G., Heim, S., Borresen-Dale, A.L. and Kallioniemi, O.P. (1996) Gain of 17q24-qter detected by comparative genomic hybridization in malignant tumors from patients with von Recklinghausen's neurofibromatosis. *Cancer Res.*, **56**, 4778-81.
7. Lothe, R.A., Smith-Sorensen, B., Hektoen, M., Stenwig, A.E., Mandahl, N., Saeter, G. and Mertens, F. (2001) Biallelic inactivation of TP53 rarely contributes to the development of malignant peripheral nerve sheath tumors. *Genes Chromosomes Cancer*, **30**, 202-6.
8. Mechttersheimer, G., Otano-Joos, M., Ohl, S., Benner, A., Lehnert, T., Willeke, F., Moller, P., Otto, H.F., Lichter, P. and Joos, S. (1999) Analysis of chromosomal imbalances in sporadic and NF1-associated peripheral nerve sheath tumors by comparative genomic hybridization. *Genes Chromosomes Cancer*, **25**, 362-9.
9. Schmidt, H., Wurl, P., Taubert, H., Meye, A., Bache, M., Holzhausen, H.J. and Hinze, R. (1999) Genomic imbalances of 7p and 17q in malignant peripheral nerve sheath tumors are clinically relevant. *Genes Chromosomes Cancer*, **25**, 205-11.
10. Schmidt, H., Taubert, H., Meye, A., Wurl, P., Bache, M., Bartel, F., Holzhausen, H.J. and Hinze, R. (2000) Gains in chromosomes 7, 8q, 15q and 17q are characteristic changes in

- malignant but not in benign peripheral nerve sheath tumors from patients with Recklinghausen's disease. *Cancer Lett*, **155**, 181-90.
11. Schmidt, H., Taubert, H., Wurl, P., Bache, M., Bartel, F., Holzhausen, H.J. and Hinze, R. (2001) Cytogenetic characterization of six malignant peripheral nerve sheath tumors: comparison of karyotyping and comparative genomic hybridization. *Cancer Genet. Cytogenet.*, **128**, 14-23.
 12. Serra, E., Puig, S., Otero, D., Gaona, A., Kruyer, H., Ars, E., Estivill, X. and Lazaro, C. (1997) Confirmation of a double-hit model for the NF1 gene in benign neurofibromas. *Am. J. Hum. Genet.*, **61**, 512-9.
 13. Serra, E., Ars, E., Ravella, A., Sanchez, A., Puig, S., Rosenbaum, T., Estivill, X. and Lazaro, C. (2001) Somatic NF1 mutational spectrum in benign neurofibromas: mRNA splice defects are common among point mutations. *Hum. Genet.*, **108**, 416-29.
 14. Ruiz-Ponte, C. , Loidi, L., Vega, A., Carracedo, A., Barros, F. (2000) Rapid real-time fluorescent PCR gene dosage test for the diagnosis of DNA duplications and deletions. *Clin Chem* 46, 1574-1582.

MOLECULAR BIOLOGY AND GENETICS OF CANCER

Genetics of Neurofibromatosis 1-Associated Peripheral Nerve Sheath Tumors

Karen Stephens*

Departments of Medicine and Laboratory Medicine, University of Washington, Seattle, Washington, USA

AQ1

INTRODUCTION

Much of our current understanding of tumorigenesis is founded on genetic studies of relatively rare individuals with inherited disorders that predispose to certain cancers, e.g., retinoblastoma^[1] and colorectal tumors.^[2,3] Such genetic studies are consistent with a model whereby normal tissues become highly malignant due to successive mutation of multiple genes that dysregulate cellular proliferation and homeostasis. Important classes of mutated genes include oncogenes (positive growth regulators), tumor suppressors (negative growth regulators), and those encoding cell cycle regulators, antiapoptotic signals, and components of the DNA replication and repair machinery. Mutation during tumorigenesis can occur at the nucleotide level as inactivation of a single gene or at the chromosomal level as losses of large segments or entire chromosomes, as a fusion of two different chromosomal segments, or as a high level amplification of a segment.^[4] Screening normal and tumor tissues of patients for common genetic alterations has been a productive strategy for identifying genes that contribute to tumor formation. This article focuses on genetic changes commonly associated with peripheral nerve sheath tumors in individuals with the autosomal dominant tumor-prone disorder neurofibromatosis 1 (NF1).

Virtually all individuals affected with NF1 develop multiple peripheral nerve sheath tumors. The most common are neurofibromas, which are benign tumors that can occur anywhere along the length of epidermal, dermal, deep peripheral (including dorsal nerve roots in the paraspinal area), or cranial nerves. They do not occur in the brain or the spinal cord proper.^[5] Although benign, neurofibromas can cause considerable morbidity by, e.g., infiltrating and functionally impairing normal tissues, causing limb hypertrophy, or masking an emerging malignancy. Some types of neurofibromas can transform into malignant peripheral nerve sheath tumors (MPNST), previously termed neurofibrosarcoma or malignant schwannoma. An estimated 20%–50% of MPNSTs are associated with NF1 disease,^[6] and they are a significant cause of the decreased life expectancy in the NF1 patient population.^[7,8] Recent population-based longitudinal studies detected an annual incidence of 1.6/1000 and a lifetime risk of 8%–13% for NF1-associated MPNST,^[9] which is much higher than detected in previous cross-sectional studies^[10] and over three orders of magnitude greater than that of the general population (~0.001%).^[11] Furthermore, NF1-associated MPNST were diagnosed at an earlier age than sporadic tumors (26 vs. 62 years, $p < 0.001$) and associated with a poorer prognosis than sporadic MPNST (5-year survival of 21 vs. 42%, $p = 0.09$).^[9]

*Correspondence: Karen Stephens, Ph.D., University of Washington, 1959 NE Pacific St., Rm I-204, Seattle, WA 98195-7720, USA; Fax: 206-685-4829; E-mail: millie@u.washington.edu.

This article reviews the genetic abnormalities that have been identified at the level of the gene, chromosome, and genome in NF1-associated neurofibromas and MPNST. Identifying commonly associated genetic alterations and the mechanisms by which they arise may potentially lead to markers for tumor staging, to new research approaches to pathogenesis, and to the identification of gene targets, which in conjunction with NF1, will be useful for mouse models.

THE MOLECULAR BASIS OF NF1

The NF1 is a common autosomal dominant disorder that affects about 1 in 3500 individuals worldwide. About 30%–50% of cases are sporadic, caused by de novo mutation in the *NF1* gene of an individual without a family history of the disorder. In addition to predisposing to tumorigenesis, NF1 is associated with characteristic changes in pigmentation and can be associated with a wide range of other manifestations such as learning disabilities and bony abnormalities (reviewed by Refs. [12–16]). All cases are caused by mutation of the *NF1* gene at chromosome 17 band q11.2, which contains 60 exons that encode the 2818 amino acid protein called neurofibromin.^[17–21] Neurofibromin is widely expressed, predominantly in the central nervous system and sensory neurons and Schwann cells of the peripheral nervous system.^[22,23] One functional domain of neurofibromin has been defined, the GAP-related domain (GRD), so called because of its structural and functional homology to mammalian p120-GAP (GTPase activating protein) and yeast genes known to regulate the Ras pathway.^[24,25] The Ras-GAP proteins function as negative regulators of Ras by catalyzing the conversion of active GTP-bound Ras to the inactive GDP-bound Ras form.^[26] In NF1-associated peripheral nerve sheath tumors, it is hypothesized that neurofibromin deficiency leads to increased activated Ras, resulting in aberrant mitogenic signaling and the consequent growth of a tumor. The identification of an NF1 patient with a missense mutation in the GRD that specifically abolished the Ras-GAP activity of neurofibromin demonstrated the importance of neurofibromin GAP function in NF1 pathogenesis.^[27] In at least some tissues, there is evidence that it is the Ras-GAP activity that accounts for the tumor suppressor function of neurofibromin. The most complete evidence comes from genetic and biochemical analyses of NF1-associated malignant myeloid disorders.^[28,29] The tumor suppressor function of *NF1* has been reviewed recently^[30–32] along with its potential as a therapeutic target.^[33]

The NF1 disease is caused by haploinsufficiency for neurofibromin. The vast majority of *NF1* mutations are not in the GRD but are distributed throughout the gene. Over 80% of mutations inactivate or predict inactivation of neurofibromin; splicing defects and sequence alterations that create a premature translation termination codon are the most common.^[34,35] About 10% of *NF1* mutations are missense,^[35,36] which are typically clustered in the GRD or an upstream cysteine/serine-rich domain that may play a role in ATP binding.^[36] Definitive evidence that neurofibromin haploinsufficiency underlies NF1 came with the identification of *NF1* whole gene deletions in an estimated 5%–10% of affected individuals.^[37,38] Mutational analyses of patients with specific features, such as plexiform neurofibroma,^[39] spinal neurofibroma,^[40] or malignant myeloid disorders,^[41] failed to detect any correlation between genotype and phenotype. A notable exception is the subset of patients heterozygous for a microdeletion spanning the entire *NF1* gene, who consistently show an early age at onset of cutaneous neurofibromas (see below).

Virtually all NF1 patients develop neurofibromas. Neurofibromas are comprised of an admixture of large-ly Schwann cells and fibroblasts, along with mast cells, endothelial cells, and pericytes.^[42,43] Although classification schemes vary, Friedman and Riccardi^[13] define four types of neurofibromas. Discrete cutaneous neurofibromas of the epidermis or dermis are the most common, typically appearing near or at puberty and increasing in number to over 100 by the fourth decade of life.^[44] They are a localized tumor of small nerves in the skin that feels fleshy and soft; they are more prevalent on the trunk but also occur frequently on the face and extremities. Discrete subcutaneous neurofibromas have a spherical or ovoid shape, feel firm or rubbery, and may be painful or tender. Deep nodular neurofibromas, also called nodular plexiform neurofibromas, involve major or minor nerves in tissues beneath the dermis. On gross pathology, they appear to grow inside the peripheral nerve, causing a fusiform enlargement, and may extend the entire length of a nerve.^[43] Diffuse plexiform neurofibromas have a cellular composition similar to that of cutaneous neurofibromas, but in contrast, they have a tendency to become locally invasive.^[5,43] Histologically, this tumor is a tangled network involving multiple nerve fascicles or branches of major nerves with poorly defined margins that makes complete surgical resection virtually impossible. Plexiform neurofibromas can be superficial with extensive involvement of underlying tissues, or they may involve deep tissues, particularly in the craniofacial region, paraspinal structures, retroperitoneum, and gastrointestinal tract.^[13] They can infiltrate soft

tissues resulting in localized hypertrophy and significant functional impairment. In contrast to other types of neurofibromas, diffuse plexiform tumors are considered congenital because they typically become evident in infancy or childhood and rarely, if ever, in late adulthood.^[45,46] In a population-based study, 32% of individuals with NF1 had a plexiform neurofibroma(s) on physical examination.^[47] Korf^[5] recently reviewed plexiform neurofibromas.

Plexiform neurofibromas, both diffuse and nodular, are at a greater risk of transforming to an MPNST than other types of neurofibromas (reviewed in Refs. [5,43,48]). Pathological examination of MPNST from individuals, both with and without NF1, most often shows an association with a neurofibroma.^[11,49-51] These data suggest that an early step in MPNST development may be preneoplastic process in the nerve sheath. Multiple pathological and molecular criteria are used to evaluate a neurofibroma for malignant transformation.^[48] Several lines of evidence are consistent with cutaneous and plexiform neurofibromas and MPNSTs being clonal tumors that arise from an ancestral Schwann cell (see below).

GENETICS OF NEUROFIBROMAGENESIS

Homozygous Inactivation of *NF1*

Homozygous inactivation of a tumor suppressor gene(s) is a fundamental mechanism of tumorigenesis. It occurs by either sequential somatic inactivation of both alleles or by a somatic mutation in the single normal homolog in individuals who inherit a germline mutation in one allele. Somatic inactivation is frequently associated with loss of heterozygosity (LOH) at the tumor suppressor locus and at multiple flanking loci (reviewed in Refs. [52,53]). Evidence for such "2nd hit" somatic *NF1* mutations in neurofibromas has been sought in support of the hypothesis that neurofibromin functions as a tumor suppressor in Schwann cells. Initial reports of LOH at *NF1*^[54] have been confirmed and extended by analyses of both primary tumor tissue and neurofibroma-derived Schwann cells. At least 25% of neurofibromas undergo LOH at *NF1*.^[55,56] The cellular admixture in neurofibromas can mask allelic loss,^[55,56] which is the likely explanation for reports that detected few, if any, tumors with LOH.^[57-62] Compelling evidence that the somatic inactivation of the *NF1* gene itself is important was provided by the identification of a 4 bp deletion in exon 4b in a cutaneous neurofibroma of a patient with a germline *NF1* microdeletion.^[63]

Subsequent analyses of cDNA from neurofibromin-derived Schwann cells showed that 19% of neurofibromas carried somatic intragenic mutations, which were typically mRNA splicing defects.^[34] Mutation frequency may be underrepresented due to the difficulty of recovering high-quality tumor RNA and the underrepresentation of mutant transcripts observed in some tumors. The latter could be attributed to mutations that induce nonsense-mediated decay or other mechanisms that affect mRNA content (reviewed in Ref. [64]) or to reduced expression for other reasons,^[34] and/or a low proportion of mutant to normal Schwann cells in some tumors.^[65,66] Homozygous inactivation of *NF1* also occurs in plexiform neurofibromas, where an estimated 40% (n = 10) showed LOH,^[67] a result confirmed by subsequent reports.^[57,58,68,69]

A predominant mechanism of somatic *NF1* inactivation in neurofibromas that underwent LOH was mitotic recombination.^[56] A 17q proximal single mitotic recombination event near the centromere of the q arm between the normal chromosome 17 and the homolog carrying the germline *NF1* mutation can generate a cell in which both *NF1* genes carry the germline mutation and all loci distal to the recombination site are identical. Less common were double recombination events that result in chromosome 17 interstitial loci showing LOH. The *NF1* mRNA in some neurofibromas is edited such that an arginine codon is changed to a nonsense codon.^[70] Although only one-third of neurofibromas examined showed a low level (<2.5%) of edited *NF1* transcripts,^[71] such modulation of neurofibromin expression may be important if, e.g., editing occurred at high frequency in transcripts from a specific minor cellular component of the tumor. In other neurofibromas, somatic mutations appear to destabilize *NF1* mRNA.^[66] Transcriptional silencing via hypermethylation of promoter regions, a prominent mechanism of inactivating other tumor suppressor genes,^[72] has not been detected in neurofibroma tissue.^[73,74] As expected from the mutational and LOH analyses, some neurofibromas had no detectable *NF1* transcripts or neurofibromin.^[75,76] A quantitative Ras activity assay demonstrated that activated Ras-GTP levels were about fourfold higher in neurofibromas than levels in non-*NF1*-associated schwannomas.^[75,77]

Neurofibromas are most likely clonal tumors derived from a Schwann cell progenitor. The detection of LOH in a tumor operationally defines it as being clonal in origin, and these data are consistent with direct marker analyses in neurofibromas.^[57,61] The LOH or other somatic mechanisms that inactivate *NF1* in a Schwann cell progenitor may be an early or initiating genetic event in neurofibromagenesis. Klewe and colleagues showed

LOH in primary neurofibroma tissue and in tumor-derived Schwann cells but not fibroblasts.^[78] Other investigators confirmed this observation.^[66,68] Two genetically distinct Schwann cell populations, *NF1*^{+/-} and *NF1*^{-/-}, were successfully cultured from 10 mutation-characterized neurofibromas, whereas tumor-derived fibroblasts carried only the germline *NF1*^{+/-} genotype.^[65] Sherman et al.^[79] used an elegant single cell Ras-GTP assay to show elevated levels in neurofibroma-derived Schwann cells but not fibroblasts. Consistent with two Schwann cell populations, only a fraction (12%–62%) of neurofibroma-derived Schwann cells had elevated Ras-GTP levels. The basis of the Schwann cell heterogeneity is not known, but the authors speculate that the cells with high Ras-GTP (presumably neurofibromin-deficient) may recruit Schwann cells with lower Ras-GTP levels (presumably the constitutional neurofibromin-haploinsufficient cells) via the synthesis of growth factors. Whether this admixture of Schwann cells is important in tumorigenesis remains to be determined; however, its observation in primary neurofibroma tissues makes it more likely. Fluorescence in situ hybridization and immunohistochemistry demonstrated that S-100 protein (Schwann cell marker) immunopositive cells in sections of four of seven primary plexiform neurofibromas were monosomic for *NF1*.^[80] Because other cells types were disomic at *NF1*, these results strongly implicate the Schwann cell as the target of the *NF1* 2nd hit mutation and verify that the results from neurofibroma-derived Schwann cells were not biased by cell culture. These data also support Schwann cell genetic heterogeneity, because the fraction of S-100 protein positive cells showing *NF1* deletion ranged from 50%–93%. Further evidence for the importance of Schwann cells in neurofibromagenesis comes from the tumorigenic properties exhibited by neurofibroma-derived cells.^[81–84] In the most comprehensive studies, Muir and colleagues^[83,84] showed that neurofibromin-deficient Schwann cells, derived from either dermal or plexiform neurofibromas, had high invasive potential and produce neurofibroma-like tumors when engrafted into peripheral nerves of *scid* mice.

Germline Alterations That May Modify Neurofibromagenesis

The considerable variable expressivity of *NF1* disease among family members with presumably the same *NF1* mutation and results of a statistical trait analysis led to the contention that variation in an individual's genetic background modified the *NF1* phenotype.^[46,85] To date, no such germline modifying

genes have been identified. However, the study of patients carrying *NF1* microdeletions has provided compelling evidence for a gene that modifies neurofibromagenesis. We first recognized that *NF1* microdeletion patients typically showed an early age at onset of localized cutaneous neurofibromas or, in cases in which age at onset could not be documented, they had significantly greater numbers of cutaneous neurofibromas relative to their age.^[38,86] It is common to observe multiple cutaneous neurofibromas during physical examination of children under age 10 that are heterozygous for an *NF1* microdeletion,^[38,87,88] whereas only about 10% in the general *NF1* population have a tumor(s) by that age.^[47] In our most severe case, a 5 year old with an *NF1* microdeletion had 51–100 tumors.^[38] The *NF1* microdeletions can be inherited from an affected parent, and in these cases, the microdeletion cosegregated with the early age at onset of neurofibromas.^[88,89] Other investigators have confirmed the early onset and heavy burden of cutaneous neurofibromas in *NF1* microdeletion patients, and over 50 such patients have been identified.^[90–98]

Most *NF1* microdeletions span 1.5 MB of DNA,^[87] which harbors the entire 350 kb *NF1* gene and at least 11 additional genes, most of unknown function.^[87,99] The microdeletions are preferentially maternal in origin^[87,91,93,100,101] and arise by homologous recombination between 60 kb misaligned paralogs (termed NF1REP) that flank the *NF1* gene.^[87] Paralogs are nonallelic DNA sequences with a high degree of identity that arose via duplication, e.g., the two functional α globin genes. Over 25 human disorders are known to be caused by gene or chromosomal rearrangements mediated by homologous recombination between paralogs, a process correctly referred to as nonallelic homologous recombination in the review by Stankiewicz and Lupski.^[102] Here, I propose that this process be called by the less awkward term of paralogous recombination and that disorders arising by this mechanism be called paralogous recombination disorders, rather than the currently used genomic disorders. Although the NF1REPs share >95% sequence identity over 60 kb of sequence, about 80% of the *NF1* deletion alleles are virtually identical because their breakpoints map to one of either two recombination hotspots of several kb in size located within the NF1REP^[103] (M. Dorschner et al., in preparation). Although the molecular basis for these hotspots is not yet known, their existence means that the majority of microdeletion patients will be deleted for the same set of genes. The early age at onset of cutaneous neurofibromas observed in several patients with larger deletions and/or different breakpoints

indicates that generation of a deletion-specific fusion gene product is unlikely.^[87]

We hypothesized that the codeletion of *NF1* and an unknown linked gene potentiates cutaneous neurofibromagenesis.^[38,87] What might be the function of the putative neurofibromagenesis-potentiating locus (*NPL*)? Here I propose two models for the early age at onset of cutaneous neurofibromas in microdeletion patients. Haploinsufficiency for *NPL* could increase the frequency of somatic 2nd hit mutations in the *NF1* gene. This could result from a genomic instability in microdeletion patients, which is intriguing in view of reports detecting cytogenetic abnormalities and microsatellite instability in some neurofibromas (see below). It would be interesting to determine if somatic *NF1* mutations in cutaneous neurofibromas of microdeletion patients occur by a predominant mechanism. Only a single tumor from each of two deletion patients have been analyzed; one had a 4 bp intragenic deletion^[63] and the other a splice site.^[65] A second model for early onset of cutaneous neurofibromas proposes that *NPL* haploinsufficiency increases the probability that a neurofibromin-deficient progenitor cell proliferates and manifests as a neurofibroma. Multiple mechanisms could be proposed. For example, *NPL* could encode (or regulate) a cytokine, cell cycle regulator, tumor suppressor, or oncogene, which exerts a positive proliferative advantage on the progenitor cell. Because of the cellular heterogeneity of neurofibromas, this model does not necessarily require that the abnormal expression of *NPL* or its putative downstream targets occur in the neurofibromin-deficient Schwann clone.

Preliminary, but intriguing evidence suggests that genetic background, other than *NF1* microdeletion, may influence the somatic inactivation of *NF1*. In patients with multiple neurofibromas, it was determined that each of the tumors showed the same type of somatic mutation event (e.g., LOH of the entire q arm or interstitial LOH).^[56] Depending on the extent of LOH and the particular genes involved, this could explain differences in the age at onset and/or numbers of neurofibromas that develop in an individual.

Somatic Alterations That May Modify Neurofibromagenesis

The *NF1*-associated neurofibromas have been analyzed for genetic abnormalities at the chromosomal level by comparative genome hybridization (CGH) and cytogenetic analyses. Comparative genome hybridization is a powerful technique to detect and map chromosomal regions with copy number imbalances in tumor

specimens (reviewed in Ref. [104]). Only two of eight neurofibromas (type not specified) examined showed chromosomal imbalances; one tumor showed three gains; the other only a single gain.^[105,106] This observation is consistent with cytogenetic studies. Although Schwann cell cultures from dermal neurofibromas had normal karyotypes, cells derived from plexiform neurofibromas had abnormalities, which in some tumors consisted of unrelated non-clonal abnormalities.^[107] One plexiform had structural abnormalities predominantly involving telomeres, which are typically associated with genomic instability in other syndromes/tumors.^[107] Wallace et al. proposed that chromosomal abnormalities might be important in the development of plexiform neurofibromas. Chromosomal abnormalities in plexiform neurofibromas may account, at least in part, for their increased risk of malignant transformation. Whether other cellular components of neurofibromas show cytogenetic abnormalities is unclear. Some neurofibroma fibroblast-like derived cultures were reported to show an increased frequency of chromosomal aberrations,^[108] whereas others were typically negative.^[109]

Conflicting data have been reported regarding the presence of microsatellite instability in *NF1*-associated neurofibromas. Some human tumors, most notably those of patients with hereditary nonpolyposis colon cancer HNPCC, show microsatellite instability, which is detected by random changes in the length of microsatellite (simple nucleotide repeats) loci. Length mutations at multiple microsatellite loci in a tumor reflect a genome-wide instability, which in the case of HNPCC is due to a defect in any of several mismatch repair genes (reviewed in Ref. [2]). Ottini et al.^[110] reported that 50% (n = 16) of neurofibromas showed altered allele lengths compared with matched normal tissue, and instability at chromosome 9 loci has also been reported.^[111] Birindelli et al.^[112] observed instability in a primary MPNST and a metastasis in one of 25 cases. However, no evidence of instability was detected in two subsequent studies of 80 neurofibromas, of which 5% appear to be of the plexiform type.^[55,73] This disparity may be due to technical differences, the number and type of microsatellite loci examined, and/or the stage of the neurofibromas. The LOH at *NF1* was not a factor, because all three studies analyzed neurofibromas that were both positive and negative. Of the eight neurofibromas with microsatellite instability, seven were unstable at only one of the five loci tested.^[110] Due to the important implications that microsatellite instability would have for neurofibromagenesis, additional loci should be examined in

these tumors, including those analyzed by the other investigators. In addition, it would be interesting to know if the neurofibromas that showed microsatellite instability were of the larger, central plexiform type, in which case they may have been transforming to malignancy. The proportion of loci that display instability is known to increase with tumor progression in HNPCC.^[113]

GENETICS OF MPNST DEVELOPMENT

Homozygous Inactivation at *NF1*

The homozygous inactivation of *NF1* in NF1-associated MPNST, first reported by Skuse et al.,^[60] has been confirmed in about 50% of tumors (n = 22) by LOH.^[67,109,112,114,115] Mutations in both *NF1* alleles have been identified in a single MPNST.^[114] Although the mechanism of LOH is not known, it does not generally involve cytogenetically detectable losses at 17q1.^[116] Furthermore, NF1-associated MPNST-derived cell lines showed decreased or absent neurofibromin and high levels of active Ras-GTP,^[117,118] and a quantitative Ras activity assay demonstrated that activated Ras-GTP levels in tumors were about 15-fold higher than levels in non-NF1-associated schwannomas.^[77] Because homozygous inactivation of *NF1* occurs in benign neurofibromas, it is considered an early or initiating event that is necessary and sufficient for neurofibromagenesis but not MPNST development. Malignant transformation is presumably driven by predisposing genetic factors in the germline and/or by additional somatic mutations and positive growth selection in a malignant precursor cell. The role of *NF1* in the development of sporadic MPNST is not clear; only about 10% of these tumors show LOH at *NF1*.^[112]

Germline Alterations That May Modify MPNST Development

Little is known about germline genetic modifiers that predispose to MPNST. Early speculation that patients with *NF1* microdeletion may be at increased risk for malignancy^[38] is now supported by indirect evidence. Mutational analysis of germline DNA from seven patients who developed MPNST determined that three (42%) were heterozygous for an *NF1* microdeletion.^[119] In another study, 2 of 17 (11%) unrelated *NF1* microdeletion patients developed MPNST, and affected first-degree relatives of two microdeletion patients had

other malignancies.^[87] Although additional cases are needed, these data suggest that the lifetime risk of MPNST in microdeletion patients may exceed the already high 10% in the general NF1 population.^[9] If so, the underlying mechanism may be essentially the same as that proposed above for early onset neurofibromagenesis. Deletion of the putative *NPL* gene could result in genomic instability or exert positive growth selection for the malignant clone. If microdeletions do predispose to both cutaneous neurofibromas and MPNST, it seems reasonable to speculate that in at least this subset of patients, either the discrete cutaneous type of neurofibroma is at increased risk of malignant transformation or the frequency of nodular or diffuse plexiform neurofibromas is high.

Evidence from two families suggests the intriguing possibility that *MLH1* deficiency predisposes to NF1 and early onset extracolonic tumors.^[120,121] Germline heterozygous inactivating mutations in *MLH1* cause inefficient DNA mismatch repair, with the consequent increase in mutation frequency and susceptibility to hereditary nonpolyposis colorectal cancer (reviewed in Ref. [122]). Two rare and independent cases of consanguineous marriages between *MLH1* heterozygous first cousins each produced two children with NF1 disease and hematological malignancies.^[120,121] The parents had no signs of NF1 and there was no family history of the disease. The *MLH1* mutations were identified, confirming homozygosity in three of the four deceased children, who presented with multiple café au lait spots (4/4), dermal neurofibromas (2/4), tibial pseudoarthrosis (1/4), non-Hodgkin's lymphoma (2/4), myeloid leukemia (2/4), and medulloblastoma (1/4). The authors suggest that these patients had a de novo postzygotic *NF1* mutation and that the *NF1* gene may be preferentially susceptible to mismatch repair deficiency. Unfortunately, the *NF1* gene was not analyzed for mutations, due in part to lack of patient tissue,^[120] which could have confirmed mutation of *NF1* and differentiated between postzygotic mutation and germline mosaicism in a parent.

Somatic Alterations in NF1-Associated MPNST

All NF1-associated MPNST showed significant chromosomal imbalances by CGH.^[105,106,123,124] Analysis of 27 total tumors from 19 NF1 patients showed an average of >7 imbalances per MPNST (Table 1). One tumor had only a single imbalance, a gain of chromosome 8.^[123] The studies led by Mechttersheimer and Schmidt,^[105,106] which include 74% of tumors examined, detected chromosomal gains more frequently than

Table 1. Chromosomal gains and losses in MPNST detected by CGH.

		NF1-associated MPNST			Sporadic MPNST		
		Loethe ^a	Mechtersheimer ^b	Schmidt ^c	Loethe ^a	Mechtersheimer ^b	Schmidt ^c
T1.4	No. tumors/No. patients	7/7	6/6	14/6	3/3	13/13	22/20
T1.5	Imbalances	52	77	188	14	176	200
T1.6	Per tumor	7.4	11.7	13.4	4.6	13.5	9.1
T1.7	Range	1-17	6-30	7-29	1-7	0-34	0-25
T1.8	Chromosome gains	14	48	139	4	125	179
T1.9	Per tumor	2	8.0	10.0	1.3	9.6	8.1
T1.10	Range	0-3	4-18	5-20	0-2	0-23	0-21
T1.11	Chromosome losses	38	29	49	10	51	33
T1.12	Per tumor	5.4	4.8	3.5	3.3	3.9	1.5
T1.13	Range	0-14	1-12	0-11	1-4	0-11	0-9

a: Ref. [123].

b: Ref. [105].

c: Ref. [106].

losses (Table 1). Each of the 20 tumors in these studies had ≥ 4 chromosomal gains. Although the results of these two studies were comparable, they differed from a third study that found chromosomal losses more prevalent than gains.^[123] The reason for the disparity is unclear; however it was also evident in the analyses of sporadic MPNST in each study (Table 1). Table 2 summarizes the chromosomal segments that most frequently showed gains in NF1-associated MPNST. The most common segments were on 17q22-q24, 17q25, 7p14, 7p21, 8q22, 8q23-q24, and 7q31. Chromosomal loss of these segments was rarely, if ever,

observed.^[105,106,123] A combined analysis of sporadic and NF1-associated MPNST revealed a significantly decreased survival rate of patients with MPNST with gains at both 7p15-21 and 17q22-qter.^[124]

In addition to chromosomal gains, CGH analyses also revealed large-scale chromosomal amplifications.^[105,106,124] One-third of MPNST of both NF1 and non-NF1 patients had at least one amplified chromosomal segment (Table 3). Although the number of tumors is small, there are differences in amplification patterns. In NF1-associated MPNST 7p and 17q22-qter, the same regions that commonly showed chromosomal

Table 2. Frequency of chromosomal gains in NF1-associated MPNST.

		% MPNST			
		Loethe ^a	Mechtersheimer ^b	Schmidt ^c	Total
T2.4	No. MPNST/No. patients	7/7	6/6	14/6	27/19
T2.5	Chromosome				
T2.6	1q33	0	50	50	37
T2.7	5p15	28	50	35	37
T2.8	7p14	28	83	71	63
T2.9	7p21	28	50	64	52
T2.10	7q31	28	33	64	48
T2.11	8q22	28	33	64	48
T2.12	8q23-q24	14	33	85	55
T2.13	15q24-q25	0	17	71	41
T2.14	17q22-q24	42	83	85	74
T2.15	17q25	71	83	78	78

a: Refs. [105,123].

b: Ref. [105].

c: Ref. [106].

gains (Table 1) were amplified frequently. The frequency of 7p amplifications may be overestimated because these four MPNST (considered as different primary tumors) were from a single patient.^[106,124] In contrast, amplifications of 5p, 8q, and 12q were the most prevalent in sporadic MPNST. There was a significant difference in the frequency of tumors with more than one chromosomal segment amplified. Only 10% of NF1-associated MPNST had more than one amplified segment, whereas the frequency was 72% in sporadic tumors (Table 3). Differences in the location and

number of chromosomal segments amplified were unlikely to be due to tumor grade, because the majority of MPNST, 14 of 20 (70%) of NF1-associated and 22 of 34 (64%) of sporadic, were grade 3 (poorly differentiated). Although amplifications were more frequent in NF1-associated than sporadic MPNST (50% vs. 32%), the number of NF1-associated tumors may be overestimated because it includes multiple tumors from the same patient. Adjustment for one tumor/patient gives a frequency of 25% (5 of 20) for NF1-associated MPNST. Similarly, there was no correlation between chromosomal

T3.1 **Table 3. Large-scale chromosomal amplifications in MPNST.^a**

T3.2	Chromosome segment amplified	No. NF1-associated MPNST ^b (N = 20)	No. sporadic MPNST ^c (N = 34)
T3.3	4q12-q13		1
T3.4	5p11-p15		1
T3.5	5p14		1
T3.6	5p15		2
T3.7	5p13-pter		2
T3.8	7p14-pter	2 ^d	1
T3.9	7p13-pter	1 ^d	
T3.10	7p12-pter	1 ^d	
T3.11	7p11-p12		1
T3.12	8q12-qter		2
T3.13	8q13		1
T3.14	8q21-q22		1
T3.15	8q22-q23		1
T3.16	8q24		1
T3.17	8q23-qter	1	
T3.18	9p21-p23	1 ^e	
T3.19	9q31-q33		1
T3.20	12p12	1 ^e	
T3.21	12p13		1
T3.22	12q13-q14		1
T3.23	12q14-q21		3
T3.24	12q24		3
T3.25	13q13-q33		1
T3.26	13q32-q33		1
T3.27	17p11-p12		1
T3.28	17q24-qter	2	
T3.29	17q22-q24	1	
T3.30	20q12-qter		1
T3.31	Xp11		1
T3.32	Xp21-p22		1
T3.33	Summary		
T3.34	% tumors with an amplification	50 (10/20)	32 (11/34)
T3.35	% tumors with >1 amplified segment	0.1 (1/10)	72 (8/11)
T3.36	% patients with ≥ 1 tumor with an amplification	30 (4/12)	32 (11/34)

a: Centromeric regions, chromosomes 19 and Y, and 1p32-p36 were not scored for technical reasons. (From Ref. [105].)

b: Refs. [105,106,124].

c: Refs. [105,124].

d: Four of five primary MPNST from one patient. (From Ref. [106].)

e: Two of four primary MPNST from one patient. (From Ref. [106].)

amplification and progression to metastasis. Analysis of tissue from a primary tumor, recurrence, and metastasis from a single patient showed a single amplification (8q12-qter) in the recurrent tumor.^[124]

Comparison of the chromosomal losses detected in the three CGH studies revealed the following five most frequent losses in 27 NF1-associated MPNST: 13q21-22 (12/27), 11q23-25 (10/27), 1p22-31 (9/27), 3q11-21 (8/27), and 17p12-pter (7/27).^[105,106,123] It is of interest that the loss of 17p12-pter was detected in 50% (7 of 14) tumors in one study^[106] and in none of the tumors of the other studies. The relatively low detection rate of chromosomal losses may be due to the decreased sensitivity of CGH in polyploid MPNST.^[125]

The CGH analysis of multiple, presumably synchronous or metachronous, primary MPNST at different sites in three NF1 patients revealed a remarkable similarity in chromosomal gains and losses.^[106,124] For example, five grade 3 (poorly differentiated) tumors of one patient each showed imbalances of +7p, -13q21, and +17q22-qter. These data showed that in the specific genetic background of each patient, a relatively limited, and defined, number of rearrangements were shared among the tumors. Similarly, nearly identical aberrations were found in different MPNST from the same patient.^[125] Although limited, these data suggest that each individual's constitutional genotype sets a certain "baseline" on which a minimal and limited number of genetic alterations are necessary and sufficient for MPNST development.

Consistent with CGH analysis, the karyotype of NF1-associated MPNST-derived cells are complex with chromosomal numbers ranging from 34 to 270 indicative of hypodiploidy, hypotriploidy, hypotetraploidy, hypertriploidy, and hypertetraploidy (Refs. [109,116,125] and references therein). Although breakpoints were frequent, a common specific breakpoint was not detected. A comparison of CGH and karyotyping in six MPNST revealed significant overlap in the most frequent gains and detected losses at 19q (3 of 6 tumors), a region not analyzed in the CGH studies.^[106,125] Plaat et al.^[116] performed a computer-assisted cytogenetic analysis of 46 MPNST reported in the literature and 7 new cases of both NF1-associated and sporadic tumors (Ref. [116] and references therein). These studies confirmed the CGH observation of high-frequency gains at chromosomes 7p and 7q and losses at 1p and 17p. However, their reported cytogenetic differences between NF1-associated and sporadic MPNST^[116] were not confirmed in later studies.^[125,126] In one study, near triploid or near tetraploid clones were associated with grade 3 tumors and a poor prognosis.^[126] The detection of a t(X;18) translocation in MPNST^[127] was not confirmed

in either sporadic^[128] or NF1-associated neurofibroma or MPNST.^[129]

Inactivating mutations in several tumor suppressor genes have been identified in NF1-associated MPNST. Both LOH and intragenic missense mutations of *TP53*^[50,62,112,130] have been detected. Like many sarcomas, NF1-associated MPNST often showed overexpression of p53 (the protein product of the *TP53* gene) as assayed by immunoreactive positivity in the nucleus.^[50,112,131,132] In keeping with findings in other tumors, this most likely is mutant p53 protein, which accumulates due to its increased stability. Mutant protein is thought to promote cancer by either complexing with and sequestering functional p53 or by complexing with p63 and p73 and blocking their normal transcription factor activities (reviewed in Ref. [133]). Immunohistochemical detection of p53 was more common in NF1-associated vs. sporadic MPNST, and it was associated with poor prognosis in NF1 children.^[132] About 50% of NF1-associated MPNST showed homozygous deletion for exon 2 of the *INK4A* gene, and over 90% were immunonegative for its protein product p16.^[112,134,135] Homozygous deletion of exon 2 results in deficiency for both p16 and p14^{ARF}, two proteins encoded by alternative splicing of *INK4A* (also known as *CDKN2A*). Both of these proteins are tumor suppressors that modulate activities of the RB and p53 pathways, which are critical for cell cycle control and tumor surveillance (reviewed in Ref. [136]). *MXI1* mutations in regions that encode known functional domains have been detected in the two NF1-associated MPNST analyzed.^[137] *Mxi1* is an agonist of the oncoprotein Myc and is thought to limit cell proliferation and help maintain the differentiated state (reviewed in Ref. [138]). *Mxi1*-deficient mice develop tumors, and *Mxi1* deficiency decreases the latency of tumors that arise in *Ink4a*-deficient mice.^[139] If additional studies show that somatic inactivation of *MXI1* is common, it would suggest a link between the pathways of *Ink4a*, Myc, and Ras in NF1-associated MPNST.^[140,141]

Several differences observed in NF1-associated MPNST are likely involved in the malignant transformation of a preexisting neurofibroma. *TP53* or *INK4A* mutations/altered expression were not detected in neurofibromas.^[50,51,54,62,67,69,112,132,134,135] Furthermore, p53-positive nuclei, typically associated with MPNST, were observed in a few cells at the transitional zone between an existing plexiform neurofibroma and an arising MPNST.^[51] One plexiform neurofibroma proximal to an MPNST did show p16 immunonegativity.^[112] Microdissection of a preexisting neurofibroma from its MPNST focal malignant process revealed 5 chromosomal imbalances in the neurofibroma, all of

721 which were novel compared to the 10 imbalances in the
 722 MPNST component.^[106] These data are consistent with
 723 a restructuring of the genome during transformation.
 724 An additional distinguishing feature of MPNST is the
 725 high labeling index of the nuclear proliferating antigen
 726 Ki67, which was correlated with reduced survival in a
 727 study that combined NF1-associated and sporadic
 728 MPNST.^[51,132,142]

729 OTHER NF1-ASSOCIATED 730 NEOPLASMS AND 731 MOUSE MODELS

732 In addition to peripheral nerve sheath tumors,
 733 individuals affected with NF1 are at increased risk for
 734 an array of other tumors. Epidemiologically associated
 735 neoplasms include medulloblastoma, pheochromocyto-
 736 ma, astrocytoma, and adenocarcinoma of the ampulla
 737 of Vater (Ref. [143] and references therein).^[144]
 738 Primarily children affected with NF1 are at increased
 739 risk for optic pathway gliomas and brainstem gliomas,
 740 rhabdomyosarcomas, and malignant myeloid leuke-
 741 mias.^[41,145-149] The NF1 patients are also at increased
 742 risk for a second malignancy, some of which may be
 743 treatment-related.^[146,150,151] In different studies, 8%–
 744 21% of NF1 patients with a first malignancy developed
 745 a second cancer, compared to a frequency of 4% in the
 746 general population.^[143] Malignancy in NF1 has been
 747 reviewed recently.^[152]

748 Although heterozygous mutant mice (*Nf1*^{+/-})
 749 develop tumors, they are not the characteristic peri-
 750 pheral nerve sheath tumors characteristic of the human
 751 disease.^[153-155] The *Nf1*-deficient mice (*Nf1*^{-/-})
 752 die in utero from cardiac defects. Mice chimeric for
 753 (*Nf1*^{-/-}) and (*Nf1*^{+/-}) cells were able to develop many
 754 microscopic plexiform neurofibromas, but dermal
 755 tumors did not develop.^[156] In addition, mice doubly
 756 heterozygous for mutations in *Nf1* and *p53* developed
 757 MPNST that showed LOH at both tumor suppressor
 758 loci.^[156,157] Recently, mice were constructed such that
 759 only their Schwann cells were *Nf1* deficient.^[158]
 760 Different tumor phenotypes were observed, depending
 761 on whether the *Nf1*-deficient Schwann cells were in an
 762 animal with an *Nf1*^{+/-} or an *Nf1*^{+/+} constitutional
 763 genotype. In the *Nf1*^{+/-} genetic background, plexiform
 764 neurofibromas composed of *Nf1*-deficient Schwann
 765 cells, and the fibroblasts and mast cells that normally
 766 occur in human neurofibromas, developed on periphe-
 767 ral nerves. In the *Nf1*^{+/+} genetic background, *Nf1*-
 768 deficient Schwann cells did not participate in neurofi-
 769 bromagenesis but did form relatively small hyperplastic
 770 lesions of the cranial nerves containing minimal mast

cells. This mouse model demonstrates that neurofibro-
 min deficiency in Schwann cells is sufficient for
 generating nascent tumor lesions, but frank plexiform
 neurofibroma development requires neurofibromin
 haploinsufficiency in cells of the surrounding tissues.

With the development of mouse models, under-
 standing the genetics, pathology, and natural history of
 human benign and malignant peripheral nerve sheath
 tumors takes on new importance. It is only by accurate
 modeling of the human disease that progress can be
 made toward therapies that can slow or halt neurofi-
 bromagenesis and reduce the high risk of malignancy
 associated with NF1 disease.

ACKNOWLEDGMENTS

This work was supported by grants DAMD17-00-
 1-0542 and DAMD 17-01-1-0721 awarded to K. S. The
 U.S. Army Medical Research Acquisition Activity, 820
 Chandler Street, Fort Detrick, Md 21702-5014 is the
 awarding and administering acquisition office. The
 content of the information does not necessarily reflect
 the position or the policy of the government, and no
 official endorsement should be inferred.

REFERENCES

1. Newsham, I.; Hadjistilianou, T.; Cavenee, W.K..
 Retinoblastoma. In *The Metabolic & Molecular
 Bases of Inherited Disease*, 8th Ed.; Scriver,
 C.R., Beaudet, A.L., Sly, W.S., Valle, D., Eds.;
 McGraw-Hill: New York, 2001; Vol. 1, 819–
 848.
2. Muller, A.; Fishel, R. Mismatch repair and the
 hereditary non-polyposis colorectal cancer syn-
 drome (HNPCC). *Cancer Investig.* **2002**, *20*,
 102–109.
3. Bodmer, W. Familial adenomatous polyposis
 (FAP) and its gene, APC. *Cytogenet. Cell Genet.*
1999, *86*, 99–104.
4. Lengauer, C.; Kinzler, K.W.; Vogelstein, B.
 Genetic instabilities in human cancers. *Nature*
1998, *396*, 643–649.
5. Korf, B.R. Plexiform neurofibromas. *Am. J. Med.*
Genet. **1999**, *89*, 31–37.
6. Sorensen, S.A.; Mulvihill, J.J.; Nielsen, A. Long-
 term follow-up of von Recklinghausen neurofi-
 bromatosis. Survival and malignant neoplasms. *N.*
Engl. J. Med. **1986**, *314*, 1010–1015.
7. Poyhonen, M.; Niemela, S.; Herva, R. Risk of

- 817 malignancy and death in neurofibromatosis. Arch.
818 Pathol. Lab. Med. **1997**, *121*, 139–143.
- 819 8. Rasmussen, S.A.; Yang, Q.; Friedman, J.M.
820 Mortality in neurofibromatosis 1: an analysis
821 using U.S. death certificates. Am. J. Hum. Genet.
822 **2001**, *68*, 1110–1118.
- 823 9. Evans, D.G.; Baser, M.E.; McGaughan, J.;
824 Sharif, S.; Howard, E.; Moran, A. Malignant
825 peripheral nerve sheath tumours in neurofibroma-
826 tosis 1. J. Med. Genet. **2002**, *39*, 311–314.
- 827 10. Huson, S.M.; Compston, D.A.; Clark, P.; Harper,
828 P.S. A genetic study of von Recklinghausen
829 neurofibromatosis in south east Wales. I. Preva-
830 lence, fitness, mutation rate, and effect of parental
831 transmission on severity. J. Med. Genet. **1989**, *26*,
832 704–711.
- 833 11. Ducatman, B.S.; Scheithauer, B.W.; Piegras,
834 D.G.; Reiman, H.M.; Ilstrup, D.M. Malignant
835 peripheral nerve sheath tumors. A clinicopathologic
836 study of 120 cases. Cancer **1986**, *57*, 2006–
837 2021.
- 838 12. Korf, B.R. Diagnosis and management of neuro-
839 fibromatosis type 1. Curr. Neurol. Neurosci. Rep.
840 **2001**, *1*, 162–167.
- 841 13. Friedman, J.M.; Riccardi, V.M. Clinical and
842 epidemiological features. In *Neurofibromatosis.*
843 *Phenotype, Natural History, and Pathogenesis*,
844 3rd Ed.; Friedman, J.M., Gutmann, D.H.,
845 MacCollin, M., Riccardi, V.M., Eds.; The
846 Johns Hopkins University Press: Baltimore,
847 1999; Vol. 1, 29–86.
- 848 14. North, K. Neurofibromatosis type 1. Am. J. Med.
849 Genet. **2000**, *97*, 119–127.
- 850 15. Gutmann, D.H.; Aylsworth, A.; Carey, J.C.; Korf,
851 B.; Marks, J.; Pyeritz, R.E.; Rubenstein, A.;
852 Viskochil, D. The diagnostic evaluation and
853 multidisciplinary management of neurofibroma-
854 tosis 1 and neurofibromatosis 2. Jama **1997**, *278*,
855 51–57.
- 856 16. Lakkis, M.M.; Tennekoon, G.I. Neurofibromato-
857 sis type 1. I. General overview. J. Neurosci. Res.
858 **2000**, *62*, 755–763.
- AQ3 859 17. Li, Y.; P, O.C.; Breidenbach, H.H.; Cawthon, R.;
860 Stevens, J.; Xu, G.; Neil, S.; Robertson, M.;
861 White, R.; Viskochil, D. Genomic organization of
862 the neurofibromatosis 1 gene (NF1). Genomics
863 **1995**, *25*, 9–18.
- 864 18. Marchuk, D.A.; Saulino, A.M.; Tavakkol, R.;
865 Swaroop, M.; Wallace, M.R.; Andersen, L.B.;
866 Mitchell, A.L.; Gutmann, D.H.; Boguski, M.;
867 Collins, F.S. cDNA cloning of the type 1 neurofi-
868 bromatosis gene: complete sequence of the NF1
869 gene product. Genomics **1991**, *11*, 931–940.
19. Wallace, M.R.; Marchuk, D.A.; Andersen, L.B.; 870AQ5
Letcher, R.; Odeh, H.M.; Saulino, A.M.; Foun- 871
tain, J.W.; Brereton, A.; Nicholson, J.; Mitchell, 872
A.L., et al. Type 1 neurofibromatosis gene: 873
identification of a large transcript disrupted in 874
three NF1 patients 1749]. Science **1990**, *249*, 875
181–186. 876
20. Viskochil, D.; Buchberg, A.M.; Xu, G.; Cawthon, 877
R.M.; Stevens, J.; Wolff, R.K.; Culver, M.; Carey, 878
J.C.; Copeland, N.G.; Jenkins, N.A., et al. De- 879
letions and a translocation interrupt a cloned gene 880
at the neurofibromatosis type 1 locus. Cell **1990**, 881
62, 187–192. 882
21. Cawthon, R.M.; Weiss, R.; Xu, G.F.; Viskochil, 883
D.; Culver, M.; Stevens, J.; Robertson, M.; Dunn, 884
D.; Gesteland, R.; O'Connell, P., et al. A major 885
segment of the neurofibromatosis type 1 gene: 886
cDNA sequence, genomic structure, and point 887
mutations. Cell **1990**, *62*, 193–201. 888
22. Daston, M.M.; Scrable, H.; Nordlund, M.; 889
Sturbaum, A.K.; Nissen, L.M.; Ratner, N. The 890
protein product of the neurofibromatosis type 1 891
gene is expressed at highest abundance in 892
neurons, Schwann cells, and oligodendrocytes. 893
Neuron **1992**, *8*, 415–428. 894
23. Huynh, D.P.; Lin, C.T.; Pulst, S.M. Expression of 895
neurofibromin, the neurofibromatosis 1 gene pro- 896
duct: studies in human neuroblastoma cells and rat 897
brain. Neurosci. Lett. **1992**, *143*, 233–236. 898
24. Buchberg, A.M.; Cleveland, L.S.; Jenkins, N.A.; 899
Copeland, N.G. Sequence homology shared by 900
neurofibromatosis type-1 gene and IRA-1 and 901
IRA-2 negative regulators of the RAS cyclic 902
AMP pathway. Nature **1990**, *347*, 291–294. 903
25. Xu, G.F.; O'Connell, P.; Viskochil, D.; Cawthon, 904
R.; Robertson, M.; Culver, M.; Dunn, D.; Stevens, 905
J.; Gesteland, R.; White, R., et al. The neurofi- 906
bromatosis type 1 gene encodes a protein related 907
to GAP. Cell **1990**, *62*, 599–608. 908
26. McCormick, F. ras GTPase activating protein: 909
signal transmitter and signal terminator. Cell 910
1989, *56*, 5–8. 911
27. Klose, A.; Ahmadian, M.R.; Schuelke, M.; 912
Scheffzek, K.; Hoffmeyer, S.; Gewies, A.; 913
Schmitz, F.; Kaufmann, D.; Peters, H.; Witting- 914
hofer, A.; Nurnberg, P. Selective disactivation of 915
neurofibromin GAP activity in neurofibromatosis 916
type 1. Hum. Mol. Genet. **1998**, *7*, 1261–1268. 917
28. Zhang, Y.Y.; Vik, T.A.; Ryder, J.W.; Srouf, E.F.; 918
Jacks, T.; Shannon, K.; Clapp, D.W. Nf1 919
regulates hematopoietic progenitor cell growth 920
and ras signaling in response to multiple cyto- 921
kines. J. Exp. Med. **1998**, *187*, 1893–1902. 922

- 923 29. The NF1 gene as a tumor suppressor in neurofi-
924 bromatosis type 1. Side, L.D., Shannon, K.M.,
925 Eds.; Bios Scientific Publishers: Oxford, 1998.
- 926 30. Cichowski, K.; Jacks, T. NF1 tumor suppressor
927 gene function: narrowing the GAP. *Cell* **2001**,
928 *104*, 593–604.
- 929 31. Zhu, Y.; Parada, L.F. Neurofibromin, a tumor
930 suppressor in the nervous system. *Exp. Cell Res.*
931 **2001**, *264*, 19–28.
- 932 32. Gutmann, D.H. The neurofibromatoses: when less
933 is more. *Hum. Mol. Genet.* **2001**, *10*, 747–755.
- 934 33. Weiss, B.; Bollag, G.; Shannon, K. Hyperactive
935 Ras as a therapeutic target in neurofibromatosis
936 type 1. *Am. J. Med. Genet.* **1999**, *89*, 14–22.
- 937 34. Serra, E.; Ars, E.; Ravella, A.; Sanchez, A.; Puig,
938 S.; Rosenbaum, T.; Estivill, X.; Lazaro, C.
939 Somatic NF1 mutational spectrum in benign
940 neurofibromas: mRNA splice defects are common
941 among point mutations. *Hum. Genet.* **2001**, *108*,
942 416–429.
- 943 35. Messiaen, L.M.; Callens, T.; Mortier, G.; Beysen,
944 D.; Vandenbroucke, I.; Van Roy, N.; Speleman,
945 F.; Paepe, A.D. Exhaustive mutation analysis of
946 the NF1 gene allows identification of 95% of
947 mutations and reveals a high frequency of unusual
948 splicing defects. *Human Mutat.* **2000**, *15*, 541–
949 555.
- 950 36. Fahsold, R.; Hoffmeyer, S.; Mischung, C.; Gille,
951 C.; Ehlers, C.; Kucukceylan, N.; Abdel-Nour, M.;
952 Gewies, A.; Peters, H.; Kaufmann, D.; Buske, A.;
953 Tinschert, S.; Nurnberg, P. Minor lesion muta-
954 tional spectrum of the entire NF1 gene does not
955 explain its high mutability but points to a
956 functional domain upstream of the GAP-related
957 domain. *Am. J. Hum. Genet.* **2000**, *66*, 790–818.
- 958 37. Kayes, L.M.; Riccardi, V.M.; Burke, W.; Bennett,
959 R.L.; Stephens, K. Large de novo DNA deletion
960 in a patient with sporadic neurofibromatosis 1,
961 mental retardation, and dysmorphism. *J. Med.*
962 *Genet.* **1992**, *29*, 686–690.
- 963 38. Kayes, L.M.; Burke, W.; Riccardi, V.M.; Bennett,
964 R.; Ehrlich, P.; Rubenstein, A.; Stephens, K.
965 Deletions spanning the neurofibromatosis 1 gene:
966 identification and phenotype of five patients. *Am.*
967 *J. Hum. Genet.* **1994**, *54*, 424–436.
- 968 39. Kluwe, L.; Friedrich, R.E.; Korf, B.; Fahsold, R.;
969 Mautner, V.F. NF1 mutations in neurofibromato-
970 sis 1 patients with plexiform neurofibromas.
971 *Human Mutat.* **2002**, *19*, 309.
- 972 40. Kaufmann, D.; Muller, R.; Bartelt, B.; Wolf, M.;
973 Kunzi-Rapp, K.; Hanemann, C.O.; Fahsold, R.;
974 Hein, C.; Vogel, W.; Assum, G. Spinal neurofi-
975 bromatosis without cafe-au-lait macules in two
families with null mutations of the NF1 gene. *976*
Am. J. Hum. Genet. **2001**, *69*, 1395–1400. *977*
41. Side, L.; Taylor, B.; Cayouette, M.; Conner, E.;
Thompson, P.; Luce, M.; Shannon, K. Homozy-
gous inactivation of the NF1 gene in bone marrow
cells from children with neurofibromatosis type 1
and malignant myeloid disorders. *N. Engl. J.*
Med. **1997**, *336*, 1713–1720. *983*
42. Lott, I.T.; Richardson, E.P., Jr. Neuropathological
findings and the biology of neurofibromatosis.
Adv. Neurol. **1981**, *29*, 23–32. *986*
43. Woodruff, J.M. Pathology of tumors of the
peripheral nerve sheath in type 1 neurofibroma-
tosis. *Am. J. Med. Genet.* **1999**, *89*, 23–30. *989*
44. Huson, S.M. Neurofibromatosis 1: a clinical and
genetic overview. In *The Neurofibromatoses: A*
Pathogenetic and Clinical Overview, 1st Ed.;
Huson, S.M., Hughes, R.A.C., Eds.; Chapman
and Hall Medical: London, 1994; 160–203. *994*
45. Waggoner, D.J.; Towbin, J.; Gottesman, G.;
Gutmann, D.H. Clinic-based study of plexiform
neurofibromas in neurofibromatosis 1. *Am. J.*
Med. Genet. **2000**, *92*, 132–135. *998*
46. Riccardi, V.M. *Neurofibromatosis, Phenotype,*
Natural History, Pathogenesis; The Johns Hop-
kins University Press: Baltimore, 1992. *1000*
47. Huson, S.M.; Harper, P.S.; Compston, D.A. Von
Recklinghausen neurofibromatosis. A clinical and
population study in south-east Wales. *Brain* **1988**,
111 (Pt 6), 1355–1381. *1005*
48. Ferner, R.E.; Gutmann, D.H. International con-
sensus statement on malignant peripheral nerve
sheath tumors in neurofibromatosis. *Cancer Res.*
2002, *62*, 1573–1577. *1009*
49. Molenaar, W.M.; Dijkhuizen, T.; van Echten, J.;
Hoekstra, H.J.; van den Berg, E. Cytogenetic
support for early malignant change in a diffuse
neurofibroma not associated with neurofibroma-
tosis. *Cancer Genet. Cytogenet.* **1997**, *97*, 70–72. *1014*
50. Leroy, K.; Dumas, V.; Martin-Garcia, N.; Fal-
zone, M.C.; Voisin, M.C.; Wechsler, J.; Revuz, J.;
Creange, A.; Levy, E.; Lantieri, L.; Zeller, J.;
Volkenstein, P. Malignant peripheral nerve
sheath tumors associated with neurofibromatosis
type 1: a clinicopathologic and molecular study of
17 patients. *Arch. Dermatol.* **2001**, *137*, 908–913. *1021*
51. Watanabe, T.; Oda, Y.; Tamiya, S.; Masuda, K.;
Tsuneyoshi, M. Malignant peripheral nerve
sheath tumour arising within neurofibroma. An
immunohistochemical analysis in the comparison
between benign and malignant components. *J.*
Clin. Pathol. **2001**, *54*, 631–636. *1027*
52. Tischfield, J.A. Loss of heterozygosity or: how I *1028*

- learned to stop worrying and love mitotic recombination. *Am. J. Hum. Genet.* **1997**, *61*, 995.
53. Fearon, E.R. Human cancer syndromes: clues to the origin and nature of cancer. *Science* **1997**, *278*, 1043–1050.
54. Colman, S.D.; Williams, C.A.; Wallace, M.R. Benign neurofibromas in type 1 neurofibromatosis (NF1) show somatic deletions of the NF1 gene. *Nat. Genet.* **1995**, *11*, 90–92.
55. Serra, E.; Puig, S.; Otero, D.; Gaona, A.; Kruyer, H.; Ars, E.; Estivill, X.; Lazaro, C. Confirmation of a double-hit model for the NF1 gene in benign neurofibromas. *Am. J. Hum. Genet.* **1997**, *61*, 512–519.
56. Serra, E.; Rosenbaum, T.; Nadal, M.; Winner, U.; Ars, E.; Estivill, X.; Lazaro, C. Mitotic recombination effects homozygosity for NF1 germline mutations in neurofibromas. *Nat. Genet.* **2001**, *28*, 294–296.
57. Daschner, K.; Assum, G.; Eisenbarth, I.; Krone, W.; Hoffmeyer, S.; Wortmann, S.; Heymer, B.; Kehrer-Sawatzki, H. Clonal origin of tumor cells in a plexiform neurofibroma with LOH in NF1 intron 38 and in dermal neurofibromas without LOH of the NF1 gene. *Biochem. Biophys. Res. Commun.* **1997**, *234*, 346–350.
58. John, A.M.; Ruggieri, M.; Ferner, R.; Upadhyaya, M. A search for evidence of somatic mutations in the NF1 gene. *J. Med. Genet.* **2000**, *37*, 44–49.
59. Stark, M.; Assum, G.; Krone, W. Single-cell PCR performed with neurofibroma Schwann cells reveals the presence of both alleles of the neurofibromatosis type 1 (NF1) gene. *Hum. Genet.* **1995**, *96*, 619–623.
60. Skuse, G.R.; Kosciolk, B.A.; Rowley, P.T. Molecular genetic analysis of tumors in von Recklinghausen neurofibromatosis: loss of heterozygosity for chromosome 17. *Genes Chromosomes Cancer* **1989**, *1*, 36–41.
61. Skuse, G.R.; Kosciolk, B.A.; Rowley, P.T. The neurofibroma in von Recklinghausen neurofibromatosis has a unicellular origin. *Am. J. Hum. Genet.* **1991**, *49*, 600–607.
62. Menon, A.G.; Anderson, K.M.; Riccardi, V.M.; Chung, R.Y.; Whaley, J.M.; Yandell, D.W.; Farmer, G.E.; Freiman, R.N.; Lee, J.K.; Li, F.P., et al. Chromosome 17p deletions and p53 gene mutations associated with the formation of malignant neurofibrosarcomas in von Recklinghausen neurofibromatosis. *Proc. Natl. Acad. Sci. U. S. A.* **1990**, *87*, 5435–5439.
63. Sawada, S.; Florell, S.; Purandare, S.M.; Ota, M.; Stephens, K.; Viskochil, D. Identification of NF1 mutations in both alleles of a dermal neurofibroma. *Nat. Genet.* **1996**, *14*, 110–112.
64. Mendell, J.T.; Dietz, H.C. When the message goes awry. Disease-producing mutations that influence mRNA content and performance. *Cell* **2001**, *107*, 411–414.
65. Serra, E.; Rosenbaum, T.; Winner, U.; Aledo, R.; Ars, E.; Estivill, X.; Lenard, H.G.; Lazaro, C. Schwann cells harbor the somatic NF1 mutation in neurofibromas: evidence of two different Schwann cell subpopulations. *Hum. Mol. Genet.* **2000**, *9*, 3055–3064.
66. Rutkowski, J.L.; Wu, K.; Gutmann, D.H.; Boyer, P.J.; Legius, E. Genetic and cellular defects contributing to benign tumor formation in neurofibromatosis type 1. *Hum. Mol. Genet.* **2000**, *9*, 1059–1066.
67. Rasmussen, S.A.; Overman, J.; Thomson, S.A.; Colman, S.D.; Abernathy, C.R.; Trimpert, R.E.; Moose, R.; Virdi, G.; Roux, K.; Bauer, M.; Rojiani, A.M.; Maria, B.L.; Muir, D.; Wallace, M.R. Chromosome 17 loss-of-heterozygosity studies in benign and malignant tumors in neurofibromatosis type 1. *Genes Chromosomes Cancer* **2000**, *28*, 425–431.
68. Eisenbarth, I.; Beyer, K.; Krone, W.; Assum, G. Toward a survey of somatic mutation of the NF1 gene in benign neurofibromas of patients with neurofibromatosis type 1. *Am. J. Hum. Genet.* **2000**, *66*, 393–401.
69. Kluwe, L.; Friedrich, R.E.; Mautner, V.F. Allelic loss of the NF1 gene in NF1-associated plexiform neurofibromas. *Cancer Genet. Cytogenet.* **1999**, *113*, 65–69.
70. Skuse, G.R.; Cappione, A.J.; Sowden, M.; Metheny, L.J.; Smith, H.C. The neurofibromatosis type I messenger RNA undergoes base-modification RNA editing. *Nucleic Acids Res.* **1996**, *24*, 478–485.
71. Mukhopadhyay, D.; Anant, S.; Lee, R.M.; Kennedy, S.; Viskochil, D.; Davidson, N.O. C→U editing of neurofibromatosis 1 mRNA occurs in tumors that express both the type II transcript and apobec-1, the catalytic subunit of the apolipoprotein B mRNA-editing enzyme. *Am. J. Hum. Genet.* **2002**, *70*, 38–50.
72. Jones, P.A. DNA methylation errors and cancer. *Cancer Res.* **1996**, *56*, 2463–2467.
73. Luijten, M.; Redeker, S.; van Noesel, M.M.; Troost, D.; Westerveld, A.; Hulsebos, T.J. Microsatellite instability and promoter methylation as possible causes of NF1 gene inactivation

- in neurofibromas. *Eur. J. Hum. Genet.* **2000**, *8*, 939–945.
74. Horan, M.P.; Cooper, D.N.; Upadhyaya, M. Hypermethylation of the neurofibromatosis type 1 (NF1) gene promoter is not a common event in the inactivation of the NF1 gene in NF1-specific tumours. *Hum. Genet.* **2000**, *107*, 33–39.
75. Guha, A. Ras activation in astrocytomas and neurofibromas. *Can. J. Neurol. Sci.* **1998**, *25*, 267–281.
76. Peters, N.; Waha, A.; Wellenreuther, R.; Friedrich, R.E.; Mautner, V.F.; Hoffmeyer, S.; Lenartz, D.; Schramm, J.; Wiestler, O.D.; von Deimling, A. Quantitative analysis of NF1 and OMGP gene transcripts in sporadic gliomas, sporadic meningiomas and neurofibromatosis type 1-associated plexiform neurofibromas. *Acta Neuropathol. (Berl)* **1999**, *97*, 547–551.
77. Guha, A.; Lau, N.; Huvar, I.; Gutmann, D.; Provias, J.; Pawson, T.; Boss, G. Ras-GTP levels are elevated in human NF1 peripheral nerve tumors. *Oncogene* **1996**, *12*, 507–513.
78. Kluwe, L.; Friedrich, R.; Mautner, V.F. Loss of NF1 allele in Schwann cells but not in fibroblasts derived from an NF1-associated neurofibroma. *Genes Chromosomes Cancer* **1999**, *24*, 283–285.
79. Sherman, L.S.; Atit, R.; Rosenbaum, T.; Cox, A.D.; Ratner, N. Single cell Ras-GTP analysis reveals altered Ras activity in a subpopulation of neurofibroma Schwann cells but not fibroblasts. *J. Biol. Chem.* **2000**, *275*, 30740–30745.
80. Perry, A.; Roth, K.A.; Banerjee, R.; Fuller, C.E.; Gutmann, D.H. NF1 deletions in S-100 protein-positive and negative cells of sporadic and neurofibromatosis 1 (NF1)-associated plexiform neurofibromas and malignant peripheral nerve sheath tumors. *Am. J. Pathol.* **2001**, *159*, 57–61.
81. Sheela, S.; Riccardi, V.M.; Ratner, N. Angiogenic and invasive properties of neurofibroma Schwann cells. *J. Cell Biol.* **1990**, *111*, 645–653.
82. Rosenbaum, T.; Rosenbaum, C.; Winner, U.; Muller, H.W.; Lenard, H.G.; Hanemann, C.O. Long-term culture and characterization of human neurofibroma-derived Schwann cells. *J. Neurosci. Res.* **2000**, *61*, 524–532.
83. Muir, D.; Neubauer, D.; Lim, I.T.; Yachnis, A.T.; Wallace, M.R. Tumorigenic properties of neurofibromin-deficient neurofibroma Schwann cells. *Am. J. Pathol.* **2001**, *158*, 501–513.
84. Muir, D. Differences in proliferation and invasion by normal, transformed and NF1 Schwann cell cultures are influenced by matrix metalloproteinase expression. *Clin. Exp. Metastasis* **1995**, *13*, 303–314.
85. Easton, D.F.; Ponder, M.A.; Huson, S.M.; Ponder, B.A. An analysis of variation in expression of neurofibromatosis (NF) type 1 (NF1): evidence for modifying genes. *Am. J. Hum. Genet.* **1993**, *53*, 305–313.
86. Kayes, L.M.; Schroeder, W.T.; Marchuk, D.A.; Collins, F.S.; Riccardi, V.M.; Duvic, M.; Stephens, K. The gene for a novel epidermal antigen maps near the neurofibromatosis 1 gene. *Genomics* **1992**, *14*, 369–376.
87. Dorschner, M.O.; Sybert, V.P.; Weaver, M.; Pletcher, B.A.; Stephens, K. NF1 microdeletion breakpoints are clustered at flanking repetitive sequences. *Hum. Mol. Genet.* **2000**, *9*, 35–46.
88. Leppig, K.A.; Kaplan, P.; Viskochil, D.; Weaver, M.; Ortenberg, J.; Stephens, K. Familial neurofibromatosis 1 microdeletions: cosegregation with distinct facial phenotype and early onset of cutaneous neurofibromata. *Am. J. Med. Genet.* **1997**, *73*, 197–204.
89. Wu, B.L.; Schneider, G.H.; Korf, B.R. Deletion of the entire NF1 gene causing distinct manifestations in a family. *Am. J. Med. Genet.* **1997**, *69*, 98–101.
90. Wu, B.L.; Austin, M.A.; Schneider, G.H.; Boles, R.G.; Korf, B.R. Deletion of the entire NF1 gene detected by the FISH: four deletion patients associated with severe manifestations. *Am. J. Med. Genet.* **1995**, *59*, 528–535.
91. Upadhyaya, M.; Ruggieri, M.; Maynard, J.; Osborn, M.; Hartog, C.; Mudd, S.; Penttinen, M.; Cordeiro, I.; Ponder, M.; Ponder, B.A.; Krawczak, M.; Cooper, D.N. Gross deletions of the neurofibromatosis type 1 (NF1) gene are predominantly of maternal origin and commonly associated with a learning disability, dysmorphic features and developmental delay. *Hum. Genet.* **1998**, *102*, 591–597.
92. Tonsgard, J.H.; Yelavarthi, K.K.; Cushner, S.; Short, M.P.; Lindgren, V. Do NF1 gene deletions result in a characteristic phenotype? *Am. J. Med. Genet.* **1997**, *73*, 80–86.
93. Lazaro, C.; Gaona, A.; Ainsworth, P.; Tenconi, R.; Vidaud, D.; Kruyer, H.; Ars, E.; Volpini, V.; Estivill, X. Sex differences in mutational rate and mutational mechanism in the NF1 gene in neurofibromatosis type 1 patients. *Hum. Genet.* **1996**, *98*, 696–699.
94. Fang, L.J.; Vidaud, D.; Vidaud, M.; Thirion, J.P. Identification and characterization of four novel large deletions in the human neurofibromatosis

- 1241 type 1 (NF1) gene. *Human Mutat.* **2001**, *18*, 549–
1242 550.
- 1243 95. Lopez Correa, C.; Brems, H.; Lazaro, C.; Estivill,
1244 X.; Clementi, M.; Mason, S.; Rutkowski, J.L.;
1245 Marynen, P.; Legius, E. Molecular studies in 20
1246 submicroscopic neurofibromatosis type 1 gene de-
1247 letions. *Human Mutat.* **1999**, *14*, 387–393.
- 1248 96. Ainsworth, P.J.; Chakraborty, P.K.; Weksberg, R.
1249 Example of somatic mosaicism in a series of de
1250 novo neurofibromatosis type 1 cases due to a ma-
1251 ternally derived deletion. *Human Mutat.* **1997**, *9*,
1252 452–457.
- 1253 97. Cnossen, M.H.; van der Est, M.N.; Breuning, H.;
1254 van Asperen, C.J.; Breslau-Siderius, E.J.; van der
1255 Ploeg, A.T.; de Goede-Bolder, A.; van den
1256 Ouweland, A.M.W.; Halley, D.J.J.; Niermeijer,
1257 M.F. Deletions spanning the neurofibromatosis
1258 type 1 gene: implications for genotype-phenotype
1259 correlations in neurofibromatosis type 1? *Human*
1260 *Mutat.* **1997**, *9*, 458–464.
- 1261 98. Jenne, D.E.; Tinschert, S.; Stegmann, E.; Reim-
1262 ann, H.; Nurnberg, P.; Horn, D.; Naumann, I.;
1263 Buske, A.; Thiel, G. A common set of at least 11
1264 functional genes is lost in the majority of NF1
1265 patients with gross deletions [in process citation].
1266 *Genomics* **2000**, *66*, 93–97.
- 1267 99. Jenne, D.E.; Tinschert, S.; Stegmann, E.; Reim-
1268 ann, H.; P. N.u.; Horn, D.; Naumann, I.; Buske,
1269 A.; Thiel, G. A common set of at least 11
1270 functional genes is lost in the majority of NF1
1271 patients with gross deletions. *Genomics* **2000**, *66*,
1272 93–97.
- 1273 100. Valero, M.C.; Pascual-Castroviejo, I.; Velasco,
1274 E.; Moreno, F.; Hernandez-Chico, C. Identifica-
1275 tion of de novo deletions at the NF1 gene: no
1276 preferential paternal origin and phenotypic anal-
1277 ysis of patients. *Hum. Genet.* **1997**, *99*, 720–726.
- 1278 101. Correa, C.L.; Brems, H.; Lazaro, C.; Marynen, P.;
1279 Legius, E. Unequal meiotic crossover: a frequent
1280 cause of NF1 microdeletions. *Am. J. Hum. Genet.*
1281 **2000**, *66*, 1969–1974.
- 1282 102. Stankiewicz, P.; Lupski, J.R. Genome architec-
1283 ture, rearrangements and genomic disorders.
1284 *Trends Genet.* **2002**, *18*, 74–82.
- 1285 103. Lopez-Correa, C.; Dorschner, M.; Brems, H.;
1286 Lazaro, C.; Clementi, M.; Upadhyaya, M.;
1287 Dooijes, D.; Moog, U.; Kehrler-Sawatzki, H.;
1288 Rutkowski, J.L.; Fryns, J.P.; Marynen, P.;
1289 Stephens, K.; Legius, E. Recombination hotspot
1290 in NF1 microdeletion patients. *Hum. Mol. Genet.*
1291 **2001**, *10*, 1387–1392.
- 1292 104. Tachdjian, G.; Aboura, A.; Lapierre, J.M.;
1293 Viguie, F. Cytogenetic analysis from DNA by
comparative genomic hybridization. *Ann. Genet.* **2000**, *43*, 147–154.
105. Mechttersheimer, G.; Otano-Joos, M.; Ohl, S.;
Benner, A.; Lehnert, T.; Willeke, F.; Moller, P.;
Otto, H.F.; Lichter, P.; Joos, S. Analysis of
chromosomal imbalances in sporadic and NF1-
associated peripheral nerve sheath tumors by
comparative genomic hybridization. *Genes Chro-
mosomes Cancer* **1999**, *25*, 362–369.
106. Schmidt, H.; Taubert, H.; Meye, A.; Wurl, P.;
Bache, M.; Bartel, F.; Holzhausen, H.J.; Hinze,
R. Gains in chromosomes 7, 8q, 15q and 17q are
characteristic changes in malignant but not in
benign peripheral nerve sheath tumors from
patients with Recklinghausen's disease. *Cancer*
Lett. **2000**, *155*, 181–190.
107. Wallace, M.R.; Rasmussen, S.A.; Lim, I.T.; Gray,
B.A.; Zori, R.T.; Muir, D. Culture of cytogenet-
ically abnormal schwann cells from benign and
malignant NF1 tumors. *Genes Chromosomes*
Cancer **2000**, *27*, 117–123.
108. Kehrler, H.; Krone, W. Spontaneous chromosomal
aberrations in cell cultures from patients with
neurofibromatosis 1. *Mutat. Res.* **1994**, *306*, 61–
70.
109. Glover, T.W.; Stein, C.K.; Legius, E.; Andersen,
L.B.; Brereton, A.; Johnson, S. Molecular and
cytogenetic analysis of tumors in von Recklin-
ghausen neurofibromatosis. *Genes Chromosomes*
Cancer **1991**, *3*, 62–70.
110. Ottini, L.; Esposito, D.L.; Richetta, A.; Carle-
simo, M.; Palmirotta, R.; Ver'i, M.C.; Battista, P.;
Frati, L.; Caramia, F.G.; Calvieri, S., et al.
Alterations of microsatellites in neurofibromas
of von Recklinghausen's disease. *Cancer Res.*
1995, *55*, 5677–5680.
111. Fagnoli, M.C.; Chimenti, S.; Peris, K. Multiple
microsatellite alterations on chromosome 9 in
neurofibromas of NF-1 patients. *J. Invest. Der-
matol.* **1997**, *108*, 812–813.
112. Birindelli, S.; Perrone, F.; Oggionni, M.; Lavar-
ino, C.; Pasini, B.; Vergani, B.; Ranzani, G.N.;
Pierotti, M.A.; Pilotti, S. Rb and TP53 pathway
alterations in sporadic and NF1-related malignant
peripheral nerve sheath tumors. *Lab. Invest.*
2001, *81*, 833–844.
113. Shibata, D.; Navidi, W.; Salovaara, R.; Li, Z.H.;
Aaltonen, L.A. Somatic microsatellite mutations
as molecular tumor clocks. *Nat. Med.* **1996**, *2*,
676–681.
114. Legius, E.; Marchuk, D.A.; Collins, F.S.; Glover,
T.W. Somatic deletion of the neurofibromatosis
type 1 gene in a neurofibrosarcoma supports a

- 1347 tumour suppressor gene hypothesis. *Nat. Genet.*
1348 **1993**, 3, 122–126.
- 1349 115. Lothe, R.A.; Slettan, A.; Saeter, G.; Brogger, A.;
1350 Borresen, A.L.; Nesland, J.M. Alterations at
1351 chromosome 17 loci in peripheral nerve sheath
1352 tumors. *J. Neuropathol. Exp. Neurol.* **1995**, 54,
1353 65–73.
- 1354 116. Plaat, B.E.; Molenaar, W.M.; Mastik, M.F.;
1355 Hoekstra, H.J.; te Meerman, G.J.; van den Berg,
1356 E. Computer-assisted cytogenetic analysis of 51
1357 malignant peripheral-nerve-sheath tumors: spo-
1358 radic vs. neurofibromatosis-type-1-associated
1359 malignant schwannomas. *Int. J. Cancer* **1999**,
1360 83, 171–178.
- 1361 117. DeClue, J.E.; Papageorge, A.G.; Fletcher, J.A.;
1362 Diehl, S.R.; Ratner, N.; Vass, W.C.; Lowy, D.R.
1363 Abnormal regulation of mammalian p21ras con-
1364 tributes to malignant tumor growth in von
1365 Recklinghausen (type 1) neurofibromatosis. *Cell*
1366 **1992**, 69, 265–273.
- 1367 118. Basu, T.N.; Gutmann, D.H.; Fletcher, J.A.;
1368 Glover, T.W.; Collins, F.S.; Downward, J.
1369 Aberrant regulation of ras proteins in malignant
1370 tumour cells from type 1 neurofibromatosis
1371 patients. *Nature* **1992**, 356, 713–715.
- 1372 119. Wu, R.; Lopez-Correa, C.; Rutkowski, J.L.;
1373 Baumbach, L.L.; Glover, T.W.; Legius, E. Germ-
1374 line mutations in NF1 patients with malignancies.
1375 *Genes Chromosomes Cancer* **1999**, 26, 376–380.
- 1376 120. Wang, Q.; Lasset, C.; Desseigne, F.; Frappaz, D.;
1377 Bergeron, C.; Navarro, C.; Ruano, E.; Puisieux,
1378 A. Neurofibromatosis and early onset of cancers
1379 in hMLH1-deficient children. *Cancer Res.* **1999**,
1380 59, 294–297.
- 1381 121. Ricciardone, M.D.; Ozcelik, T.; Cevher, B.;
1382 Ozdag, H.; Tuncer, M.; Gurgey, A.; Uzunalimo-
1383 glu, O.; Cetinkaya, H.; Tanyeli, A.; Erken, E.;
1384 Ozturk, M. Human MLH1 deficiency predisposes
1385 to hematological malignancy and neurofibroma-
1386 tosis type 1. *Cancer Res.* **1999**, 59, 290–293.
- AQ4 1387 122. Boland, C.R.
- 1388 123. Lothe, R.A.; Karhu, R.; Mandahl, N.; Mertens, F.;
1389 Saeter, G.; Heim, S.; Borresen-Dale, A.L.; Kallio-
1390 niemi, O.P. Gain of 17q24-qter detected by com-
1391 parative genomic hybridization in malignant tu-
1392 mors from patients with von Recklinghausen's
1393 neurofibromatosis. *Cancer Res.* **1996**, 56, 4778–
1394 4781.
- 1395 124. Schmidt, H.; Wurl, P.; Taubert, H.; Meye, A.;
1396 Bache, M.; Holzhausen, H.J.; Hinze, R. Genomic
1397 imbalances of 7p and 17q in malignant peripheral
1398 nerve sheath tumors are clinically relevant. *Genes*
1399 *Chromosomes Cancer* **1999**, 25, 205–211.
125. Schmidt, H.; Taubert, H.; Wurl, P.; Bache, M.; 1400
Bartel, F.; Holzhausen, H.J.; Hinze, R. Cytoge- 1401
netic characterization of six malignant peripheral 1402
nerve sheath tumors: comparison of karyotyping 1403
and comparative genomic hybridization. *Cancer* 1404
Genet. Cytogenet. **2001**, 128, 14–23. 1405
126. Mertens, F.; Dal Cin, P.; De Wever, I.; Fletcher, 1406
C.D.; Mandahl, N.; Mitelman, F.; Rosai, J.; 1407
Rydholm, A.; Sciort, R.; Tallini, G.; van Den 1408
Berghe, H.; Vanni, R.; Willen, H. Cytogenetic 1409
characterization of peripheral nerve sheath tu- 1410
mours: A report of the CHAMP study group. *J.* 1411
Pathol. **2000**, 190, 31–38. 1412
127. O'Sullivan, M.J.; Kyriakos, M.; Zhu, X.; Wick, 1413
M.R.; Swanson, P.E.; Dehner, L.P.; Humphrey, 1414
P.A.; Pfeifer, J.D. Malignant peripheral nerve 1415
sheath tumors with t(X;18). A pathologic and 1416
molecular genetic study. *Mod. Pathol.* **2000**, 13, 1417
1336–1346. 1418
128. Ladanyi, M.; Woodruff, J.M.; Scheithauer, B.W.; 1419
Bridge, J.A.; Barr, F.G.; Goldblum, J.R.; Fisher, 1420
C.; Perez-Atayde, A.; Dal Cin, P.; Fletcher, C.D.; 1421
Fletcher, J.A. Re: O'Sullivan MJ, Kyriakos M, 1422
Zhu X, Wick MR, Swanson PE, Dehner LP, 1423
Humphrey PA, Pfeifer JD: malignant peripheral 1424
nerve sheath tumors with t(X;18). A pathologic and 1425
molecular genetic study. *Mod pathol* 1426
2000;13:1336–46. *Mod. Pathol.* **2001**, 14, 733–737. 1427
129. Liew, M.A.; Coffin, C.M.; Fletcher, J.A.; Hang, 1428
M.T.; Tanito, K.; Niimura, M.; Viskochil, D. 1429
Peripheral nerve sheath tumors from patients with 1430
neurofibromatosis type 1 do not have the chro- 1431
mosomal translocation t(X;18). *Pediatr. Dev.* 1432
Pathol. **2002**, 5, 165–169. 1433
130. Legius, E.; Dierick, H.; Wu, R.; Hall, B.K.; 1434
Marynen, P.; Cassiman, J.J.; Glover, T.W. TP53 1435
mutations are frequent in malignant NF1 tumors. 1436
Genes Chromosomes Cancer **1994**, 10, 250–255. 1437
131. Halling, K.C.; Scheithauer, B.W.; Halling, A.C.; 1438
Nascimento, A.G.; Ziesmer, S.C.; Roche, P.C.; 1439
Wollan, P.C. p53 expression in neurofibroma and 1440
malignant peripheral nerve sheath tumor. An 1441
immunohistochemical study of sporadic and 1442
NF1-associated tumors. *Am. J. Clin. Pathol.* 1443
1996, 106, 282–288. 1444
132. Liapis, H.; Marley, E.F.; Lin, Y.; Dehner, L.P. p53 1445
and Ki-67 proliferating cell nuclear antigen in 1446
benign and malignant peripheral nerve sheath 1447
tumors in children. *Pediatr. Dev. Pathol.* **1999**, 2, 1448
377–384. 1449
133. Guimaraes, D.P.; Hainaut, P. TP53: a key gene in 1450
human cancer. *Biochimie* **2002**, 84, 83–93. 1451
134. Kourea, H.P.; Orlow, I.; Scheithauer, B.W.; 1452

- 1453 Cordon-Cardo, C.; Woodruff, J.M. Deletions of
1454 the INK4A gene occur in malignant peripheral
1455 nerve sheath tumors but not in neurofibromas.
1456 *Am. J. Pathol.* **1999**, *155*, 1855–1860.
- 1457 135. Nielsen, G.P.; Stemmer-Rachamimov, A.O.; Ino,
1458 Y.; Moller, M.B.; Rosenberg, A.E.; Louis, D.N.
1459 Malignant transformation of neurofibromas
1460 in neurofibromatosis 1 is associated with
1461 CDKN2A/p16 inactivation. *Am. J. Pathol.* **1999**,
1462 *155*, 1879–1884.
- 1463 136. Sherr, C.J. The INK4a/ARF network in tumour
1464 suppression. *Nat. Rev., Mol. Cell Biol.* **2001**, *2*,
1465 731–737.
- 1466 137. Li, X.J.; Wang, D.Y.; Zhu, Y.; Guo, R.J.; Wang,
1467 X.D.; Lubomir, K.; Mukai, K.; Sasaki, H.;
1468 Yoshida, H.; Oka, T.; Machinami, R.; Shinmura,
1469 K.; Tanaka, M.; Sugimura, H. Mx1 mutations in
1470 human neurofibrosarcomas. *Jpn. J. Cancer Res.*
1471 **1999**, *90*, 740–746.
- 1472 138. Foley, K.P.; Eisenman, R.N. Two MAD tails:
1473 what the recent knockouts of Mad1 and Mx1 tell
1474 us about the MYC/MAX/MAD network. *Bio-*
1475 *chim. Biophys. Acta* **1999**, *1423*, M37–M47.
- 1476 139. Schreiber-Agus, N.; Meng, Y.; Hoang, T.; Hou,
1477 H., Jr.; Chen, K.; Greenberg, R.; Cordon-Cardo,
1478 C.; Lee, H.W.; DePinho, R.A. Role of Mx1 in
1479 ageing organ systems and the regulation of
1480 normal and neoplastic growth. *Nature* **1998**,
1481 *393*, 483–487.
- 1482 140. Serrano, M.; Gomez-Lahoz, E.; DePinho, R.A.;
1483 Beach, D.; Bar-Sagi, D. Inhibition of ras-induced
1484 proliferation and cellular transformation by
1485 p16INK4. *Science* **1995**, *267*, 249–252.
- 1486 141. Pomerantz, J.; Schreiber-Agus, N.; Liegeois, N.J.;
1487 Silverman, A.; Alland, L.; Chin, L.; Potes, J.;
1488 Chen, K.; Orlow, I.; Lee, H.W.; Cordon-Cardo,
1489 C.; DePinho, R.A. The Ink4a tumor suppressor
1490 gene product, p19Arf, interacts with MDM2 and
1491 neutralizes MDM2's inhibition of p53. *Cell* **1998**,
1492 *92*, 713–723.
- 1493 142. Kindblom, L.G.; Ahlden, M.; Meis-Kindblom,
1494 J.M.; Stenman, G. Immunohistochemical and
1495 molecular analysis of p53, MDM2, proliferating
1496 cell nuclear antigen and Ki67 in benign and ma-
1497 lignant peripheral nerve sheath tumours. *Vir-*
1498 *chows Arch.* **1995**, *427*, 19–26.
- 1499 143. Mulvihill, J.J. Malignancy: epidemiologically
1500 associated cancers. In *The Neurofibromatoses: A*
1501 *pathogenetic and Clinical Overview*, 1st Ed.,
1502 Huson, S.M., Hughes, R.A.C., Eds.; Chapman
1503 & Hall Medical: London, 1994; 487.
- 1504 144. Koch, C.A.; Vortmeyer, A.O.; Huang, S.C.;
1505 Alesci, S.; Zhuang, Z.; Pacak, K. Genetic aspects
of pheochromocytoma. *Endocr. Regul.* **2001**, *35*,
43–52.
- 1506 145. Listernick, R.; Charrow, J.; Gutmann, D.H.
1507 Intracranial gliomas in neurofibromatosis type
1508 1. *Am. J. Med. Genet.* **1999**, *89*, 38–44.
- 1509 146. Gutmann, D.H.; Gurney, J.G. Other malignan-
1510 cies. In *Neurofibromatosis. Phenotype, Natural*
1511 *History, and Pathogenesis*; Friedman, J.M.,
1512 Buttmann, D.H., MacCollin, M., Riccardi,
1513 V.M., Eds.; The Johns Hopkins University
1514 Press: Baltimore, 1999; 231–249.
- 1515 147. Kluwe, L.; Hagel, C.; Tatagiba, M.; Thomas, S.;
1516 Stavrou, D.; Ostertag, H.; von Deimling, A.;
1517 Mautner, V.F. Loss of NF1 alleles distinguish
1518 sporadic from NF1-associated pilocytic astrocy-
1519 tomas. *J. Neuropathol. Exp. Neurol.* **2001**, *60*,
1520 917–920.
- 1521 148. Shannon, K.M.; O'Connell, P.; Martin, G.A.;
1522 Paderanga, D.; Olson, K.; Dinndorf, P.; McCorm-
1523 ick, F. Loss of the normal NF1 allele from the
1524 bone marrow of children with type 1 neurofibro-
1525 matosis and malignant myeloid disorders. *N.*
1526 *Engl. J. Med.* **1994**, *330*, 597–601.
- 1527 149. Matsui, I.; Tanimura, M.; Kobayashi, N.;
1528 Sawada, T.; Nagahara, N.; Akatsuka, J. Neurofib-
1529 romatosis type 1 and childhood cancer. *Cancer*
1530 **1993**, *72*, 2746–2754.
- 1531 150. Maris, J.M.; Wiersma, S.R.; Mahgoub, N.;
1532 Thompson, P.; Geyer, R.J.; Hurwitz, C.G.H.;
1533 Lange, B.J.; Shannon, K.M. Monosomy 7
1534 myelodysplastic syndrome and other second
1535 malignant neoplasms in children with neurofib-
1536 romatosis type 1. *Cancer* **1997**, *79*, 1438–1446.
- 1537 151. Mahgoub, N.; Taylor, B.R.; Le Beau, M.M.;
1538 Gratiot, M.; Carlson, K.M.; Atwater, S.K.; Jacks,
1539 T.; Shannon, K.M. Myeloid malignancies in-
1540 duced by alkylating agents in Nf1 mice. *Blood*
1541 **1999**, *93*, 3617–3623.
- 1542 152. Korf, B.R. Malignancy in neurofibromatosis type
1543 1. *Oncologist* **2000**, *5*, 477–485.
- 1544 153. Jacks, T.; Shih, T.S.; Schmitt, E.M.; Bronson,
1545 R.T.; Bernards, A.; Weinberg, R.A. Tumour pre-
1546 disposition in mice heterozygous for a targeted
1547 mutation in Nf1. *Nat. Genet.* **1994**, *7*, 353–361.
- 1548 154. Brannan, C.I.; Perkins, A.S.; Vogel, K.S.; Ratner,
1549 N.; Nordlund, M.L.; Reid, S.W.; Buchberg, A.M.;
1550 Jenkins, N.A.; Parada, L.F.; Copeland, N.G.
1551 Targeted disruption of the neurofibromatosis
1552 type-1 gene leads to developmental abnormalities
1553 in heart and various neural crest-derived tissues.
1554 *Genes Dev.* **1994**, *8*, 1019–1029.
- 1555 155. Tischler, A.S.; Shih, T.S.; Williams, B.O.; Jacks,
1556 T. Characterization of pheochromocytomas in a
1557 1558

- 1559 mouse strain with a targeted disruptive mutation
 1560 of the neurofibromatosis gene *Nf1*. *Endocr.*
 1561 *Pathol.* **1995**, 6, 323–335.
- 1562 156. Cichowski, K.; Shih, T.S.; Schmitt, E.; Santiago,
 1563 S.; Reilly, K.; McLaughlin, M.E.; Bronson, R.T.;
 1564 Jacks, T. Mouse models of tumor development
 1565 in neurofibromatosis type 1. *Science* **1999**, 286,
 1566 2172–2176.
157. Vogel, K.S.; Klesse, L.J.; Velasco-Miguel, S.; 1567
 Meyers, K.; Rushing, E.J.; Parada, L.F. Mouse 1568
 tumor model for neurofibromatosis type 1. 1569
Science **1999**, 286, 2176–2179. 1570
158. Zhu, Y.; Ghosh, P.; Charnay, P.; Burns, D.K.; 1571
 Parada, L.F. Neurofibromas in *NF1*: Schwann 1572
 cell origin and role of tumor environment. 1573
Science **2002**, 296, 920–922. 1574